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Abstract 
 
EFFECT OF QUERCETIN AND EPIGALLOCATECHIN-3-GALLATE ON ANTI-
INFLAMMATORY ACTIVITY IN VITRO AND IN VIVO 
 
Krista M Kennerly 
B.S., Appalachian State University 
M.S., Appalachian State University 
 
 
Chairperson:  Dru A. Henson, Ph.D. 
 
 
The objectives of this study were two-fold: first, to elucidate quercetin’s use as an 
anti-inflammatory neutraceutical in vitro by comparing supplementation of quercetin 
aglycone to physiologically relevant quercetin conjugates in lipopolysaccharide (LPS) 
stimulated human peripheral blood mononuclear cells (PBMCs) in culture.  In addition, this 
study attempted to determine the optimal dose and combination of quercetin (Q) and 
epigallocatechin gallate enriched green tea extract (EGCG) required to optimize performance 
during consecutive days of exercise in mice.   
For in vitro experiments, PBMCs (1x106 cells/ml), isolated from venous peripheral 
blood in healthy adults, were incubated (37°C, 5% CO2) for 1 hour with various 
concentrations of either quercetin, quercetin-3’-sulfate (Q3’S), or quercetin-3-glucuronide 
(Q3GlcA) (1-50µM) dissolved in <0.1% DMSO, prior to 23 hours of LPS stimulation.  A 
succinate dehydrogenase activity assay was then used to assess cell viability.   
For in vivo experimentation, C57BL/6J mice (n=176) were randomly assigned to one 
of five groups: control, 6.25 mg Q/kg and 1.25 mg EGCG/kg (Q/EGCG low), 12.5 mg Q/kg 
v 
and 2.5 mg EGCG/kg (Q/EGCG mid), 25 mg Q/kg and 5 mg EGCG/kg (Q/EGCG high), and 
25 mg Q/kg (Q).  Mice were supplemented for 3 and 14 days (n=12 animals per group).  For 
the last three days of the dosing cycle, mice were run on a treadmill at 14m/min for up to 2.5 
hours.  Cell culture supernatant and murine plasma concentrations of inflammatory cytokines 
were determined by either enzyme linked immunoabsorbant assay (ELISA) or using an 
electrochemiluminescence-based solid phase sandwich immunoassay. 
Quercetin caused significant decreases (P<0.05) in LPS-stimulated TNF-a, IL-1β, 
and IL-6 secretion levels at concentrations equal to or greater than 25 µM, indicating an anti-
inflammatory role of quercetin aglycone in vitro.  However, physiologically relevant 
quercetin conjugates, Q3’S and Q3GlcA, failed to elicit the same significant effect.  In vivo, 
plasma IL-10 was significantly reduced in all 14-day quercetin supplemented mice compared 
to control following exhaustive exercise.  Despite this, quercetin supplementation failed to 
cause a reduction in any other plasma cytokine measure and failed to improve exercise 
performance in mice.  Moreover, the addition of EGCG at a 5:1 ratio failed to augment any 
anti-inflammatory or performance enhancing effect. 
In conclusion, while quercetin aglycone supplementation elicited a robust anti-
inflammatory effect on human PBMCs in vitro, this effect was lost upon metabolic sulfation 
or glucuronidation.  In mice, 14-day quercetin supplementation significantly decreased post-
exercise plasma IL-10, but failed to alter any other cytokine measure or boost exercise 
performance, even upon addition of EGCG. 
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Chapter 1: Introduction 
Nutritional immunology and its application in exercise science has been the endeavor of an 
increasing number of scientists over the past couple of decades.  Interest grew following seminal 
studies that observed significant changes between resting and post-exercise immune measures1.  This 
immunologic change culminates into transient immunosuppression following strenuous, exhaustive 
exercise and directly correlates with the physiological stress of an athlete.  Epidemiological studies 
done on endurance athletes following elite competition suggest that this ‘open window’ of impaired 
immunity increases the risk for upper respiratory tract infections (URTIs)2,3.  Despite the fact that the 
mechanism for this theory remains unsubstantiated, endurance athletes may benefit from 
neutraceuticals capable of mitigating potentially superfluous immune responses, such as 
inflammation, that develop during exhaustive competition. 
To date the importance and specific function of the immune system in skeletal muscle 
recovery following exercise has been poorly understood.  Important questions that remain 
unanswered are, what degree of inflammation incurred during exercise is necessary and when might it 
be detrimental to the resting health of an elite athlete.  Many athletes self-prescribe nonsteroidal anti-
inflammatory drugs (NSAIDs), like Ibuprofen, that can additionally exacerbate inflammation under 
certain conditions such as endurance events like marathons and ultra marathons4,5.  Subsequently, 
research investigating alternative treatment options has intensified, especially with naturally occurring 
compounds, such as flavonoids, or their synthetic derivatives.  The pharmacological potency of this 
phytochemical group was formally recognized in the early 1980s and since that time, numerous 
papers have been published on their effect on innate leukocyte function6.  Quercetin is one such 
flavonoid that has been highly investigated in this manner, although claims on its effectiveness as an 
anti-inflammatory agent in vivo have been disparate and unsubstantiated in humans. 
The purpose of the preliminary review herein was three-fold: first, to give the reader a 
thorough review of the current literature on the propagation of sterile inflammation in skeletal muscle, 
including specific roles for mast cells, neutrophils, and macrophages in this context.  It should be 
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noted that it is beyond the scope of this thesis to discuss similar studies conducted on other innate cell 
types, such as dendritic cells and NK cells, and on leukocytes involved in humoral immune function.  
The next aim was to give a detailed description of the intercellular signaling pathway that activates 
canonical nuclear factor kappa-light-chain-enhancer of activated B cells  (NF-kB), which is 
responsible for regulating expression of many of the pro-inflammatory genes in M1 macrophages.  
Lastly, this review will cover detailed descriptions of the flavonoids quercetin and epigallocatechin-3-
gallate (EGCG), as well a comprehensive review of studies assessing quercetin’s anti-inflammatory 
potential as assessed both in vitro and in vivo. 
   
 
 
3 
Chapter 2: Review of Literature 
2.1 Systemic Immune Perturbations following Exercise 
2.1.1 Immune status following intensive and prolonged exercise 
It has been well established in the literature that heavy exertion during exercise has 
significant acute and chronic effects on the immune system.  This can be especially appreciated in the 
differential level of circulating plasma cytokines measured pre- and post-exercise.  Cytokines known 
to increase markedly after exhaustive exercise include interleukin (IL)-6, IL-10, IL-8, IL-1ra, 
granulocyte colony-stimulating factor, monocyte chemoattractant protein 1 (MCP-1), macrophage 
inflammatory protein 1β, tumor necrosis factor-α (TNF-α), and macrophage migration inhibitory 
factor4,7–15.  Concomitant with these cytokine perturbations, an athlete undergoing intense and 
prolonged exercise, during which muscle microtrauma and oxidative stress are thought to be 
imminent, is said to develop suppressed immune function in respect to natural killer (NK) cell 
cytotoxicity, granulocyte respiratory burst activity, nasal and salivary immunoglobulin A (sIgA) 
secretion, delayed type hypersensitivity, and lymphocyte proliferative responses, as well as drastic 
changes in circulating immune cell populations15–19.  The mechanistic cause of these immune 
perturbations in elite athletes, which can range between 3 and 72 hours, remains elusive, however 
some speculate that this “open window” in immune surveillance increases an athlete’s susceptibility 
to bacterial and viral infection20,21. 
2.1.2 Open window theory 
Several epidemiological studies support the “open window theory” of immunosuppression 
following exhaustive exercise, reporting increases in upper respiratory tract infection (URTI) risk in 
the one to two weeks following competitive endurance events2,3,22.  Immediately following a Los 
Angeles marathon race, 12.9% of runners reported URTI incidences compared to 2.2% of control 
marathon runners not participating in the race, with incidence in participants increasing to 40% in the 
2 months following the race.  After controlling for various cofounders, it was determined that training 
more than 96 km/week increased URTI risk two fold compared to those training for less than 32 
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km/week2.  In a subsequent study, increased URTI risk was noted in one out of four ultramarathon 
runners 2 weeks following a 160-km event23.  Similar findings have also been reported in both human 
and mouse studies22,24,25.  No studies suggested that any amount of endurance exercise could increase 
infection risk.  On the contrary, out of the 2300 marathon runners training for the Los Angeles 
marathon, URTI risk wasn’t significantly elevated until training distances exceeded 100-km per 
week2. 
Despite the overwhelming implication that significant immune perturbations observed post-
exercise might put one at increased risk of URTIs, direct evidence linking these two phenomena is 
still lacking26.  Of the notable immune dysfunctions experienced after rigorous exercise, the only 
potential markers that have significantly correlated with URTI risk have been relative low sIgA, a 
dominant immunoglobulin isotype on mucosal surfaces, and high IL-10 secretion from antigen-
stimulated whole blood cultures27–30.  Tomasi et al. (1982) were first to report this relationship in 
athletes after finding decreased sIgA in eight elite Nordic skiers competing in a national cross-country 
skiing event.  Subsequent studies have reported this same phenomenon in athletes undergoing 
endurance events of at least 90 minute duration, including cyclists, marathon runners, and 
triathletes31–34. 
 Despite sIgA output’s ability to predict URTI risk on a group level, the level of individual 
predictive power is generally more suspect.  Of runners completing a 160-km ultramarathon, sIgA 
secretion rate had an overall predictive value of 55%, since approximately half of non-URTI subjects 
experienced at least a 50% drop in sIgA output, proving to be false predictions.  Other contributing 
factors need to be discovered before the predictive power of sIgA output can be established, since no 
other factors concerning demographic, training, or immune status have been able to account for this 
risk23.  In short, substantiating the open window theory will require a better understanding of the 
immune system’s response to exercise. 
2.2 The Major Immune Players in Skeletal Muscle Damage and Repair 
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 The immune system plays a pivotal role in exercise by mediating tissue repair and 
regeneration within skeletal muscle.  For this to occur, concisely regulated crosstalk between immune 
cells and myofibers is played out in an adaptable orchestration of paracrine, autocrine, and contact 
interactions.  Local acute immune responses at the site of injured myofibers can be divided into two 
phases, an inflammatory period, in which leukocytes repair damaged tissue by coordinating the 
removal of necrotic cells and their debris, and myofiber regeneration.  Literature addressing the 
impact of necrotic fibers on specific immune cell subsets in response to exercise is limited, with many 
studies not exploring the intricacy of phenotypes that can exist within classically defined 
macrophages, dendritic cells, etc.  However, models of acute injury do give a degree of insight into 
how innate immunity may function in the muscle microenvironment during an athlete’s hypothetical 
open window.  
Prior to discussing the literature on acute injury in murine skeletal muscle, a disclaimer must 
be said on relating these findings to exercise-induced inflammation in human studies.  Many animal 
studies have provided evidence linking inflammation to exercise-induced muscle damage35–39.  
However, establishing this paradigm in humans has proven far more difficult and has recently been a 
topic of extensive review by Paulsen et al40.  The biggest point of contention has been whether or not 
muscle damage is indeed occurring in various exercise protocols and if so what the most appropriate 
way to assess this damage is.  The most direct approach has been histological analysis of muscle 
biopsies, however this can be unpleasant for study participants and at times unreliable since the 
procedure itself could incite inflammation.  Moreover, assessing cytokine signaling and cellular 
interactions typical of inflammation using homogenized tissue could be problematic, since data would 
be presented as tissue- instead of cell-specific expression profiles.  Animal models suggest that during 
muscular repair/regenerative processes the anatomical location and functional phenotype of immune 
cells can vary significantly at any given time, and to date no experimental procedures involving 
humans has been able to extensively explore this40.  Currently, animal studies describe methods for 
obtaining viable cell populations by gentling digesting with 0.1% collagenase B followed by a 
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blocking step with anti-CD16 and anti-CD32 to preclude macrophage activation and adhesion to 
plastic41. 
In addition, it must also be pointed out that while human and murine immune systems are 
highly similar there are fundamental differences to be considered42.  For instance, in humans 
plasma/serum creatine kinase (CK) activity peaks after 4-7 days43–47, while animal models report this 
occurrence 1-3 days following contraction-induced, skeletal muscle injury48–54.  It is also worth noting 
that while the predominant leukocyte in human blood are neutrophils (50-70% neutrophils, 30-50% 
lymphocytes), the prevalent leukocyte in mouse blood are lymphocytes (75-90% lymphocytes, 10-
25% neutrophils)55.   
Furthermore, as the mechanisms of acute inflammation during muscle injury are discussed, 
bare in mind that immune responses that occur in response to exercise are variable and may not 
always reflect findings in acute injury models conducted in mice.  In fact the majority of murine 
models used to investigate skeletal muscle inflammation on a cellular level represent the extreme in 
expected damage during exercise and include acute muscle damage from reloading after hindlimb 
suspension, injection of histotoxic compounds, ischemia-reperfusion 56–63.  At the other end of the 
spectrum models, such as relatively mild exercise-induced muscle damage (EIMD) protocols produce 
less of an inflammatory response with little to no neutrophil accumulation51.  No studies to date have 
looked at the effect of heavy exertion during exercise on specific murine innate immune cell 
subpopulations in vivo.  During exercise the extent to which muscle damage could occur is said to be 
relative to the intensity and duration of the activity, as well as individual training adaptations4,15 
Furthermore, extrapolating findings from acute muscle injury models is problematic due to the 
influence of exercise specific changes in stress hormones, stimulation of the sympathetic nervous 
system, body temperature changes, increases in blood flow, dehydration, diet, and supplement use on 
functional immunity4,13,20,64,65.  
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2.2.1 Mast cells: Instigation of innate immunity in skeletal muscle 
  Necrotic cells resulting from acute injury within skeletal muscle initiate an inflammatory 
response involving marked immune cell infiltration into the affected tissue.  Again, it should be 
stressed that the dynamics and magnitude of this response is dependent on the intensity and duration 
of the exercise performed20.  In many ways this form of ‘sterile inflammation’ is similar to the classic 
inflammatory response instigated by microbes, however it does have important distinctions66.  
Principally, local activation of innate effectors is not incited by foreign pathogens, but instead by 
endogenous proteins and nucleic acids released from the apoptotic cells, which act as damage 
associated molecular patterns (DAMPs).  DAMPs have been described in many necrotic tissue types 
and include heat shock proteins67, S100 calcium-binding proteins68, ATP69, high mobility group box 1 
(Hmgb1)70, as well as mitochondrial formyl peptides and DNA71.  Interestingly, several caspases 
integral in programmed cell death or apoptosis are capable of deactivating DAMPs.  If this were not 
the case then the death of any cell within the body could potentially trigger an inflammatory response.  
Moreover, release of activated DAMPs from solely necrotic tissue allows sentinel immune cells 
(macrophages, dendritic cells, and mast cells) to specifically distinguish between necrotic death due 
to sterile injury or infection and homeostatic cell turnover 72. 
One of the first instigators of sterile inflammation in skeletal muscle characterized by an 
immediate exudate neutrophil infiltrate is the resident mast cell.  These cells are derived from 
CD13+CD34+CD117+ (otherwise known as KIT) hematopoietic progenitors in the bone marrow and 
like monocytes, can only terminate their differentiation in peripheral tissue.  Stimulation of resident 
mast cells can induce degranulation, release of eicosanoids, and expression of various chemokines 
and cytokines that elicit either adaptive or innate effects depending on the tissue-specific 
microenvironment73.   
During sterile injury, it has been shown that mast cells can specifically respond to ST2/IL-
1RAcP ligand IL-33 released from necrotic structural cells.  In addition to exogenous functions, this 
relatively new addition to the IL-1 family is said to have transcriptional regulatory properties and 
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associate with chromatin in the nucleus74.  However, human skeletal muscle does not express IL-33 
under steady state and its expression in contracting muscle is unknown75.  Other known DAMPs 
released from skeletal muscle include HMGB1, uric acid, and adenosine.  Yet supernatant from 
necrotic mouse embryonal fibroblasts (MEFs) isolated from HMGB1-/- mice, A2AR-/- and A3R-/- 
(adenosine specific receptors) mice, or treated with the uric acid production inhibitor allopurinol 
failed to influence mast cell activation.  Despite the implications of these findings, the in vitro design 
of this study utilized phenotypically immature mast cells that may not recapitulate the mature 
phenotype in vivo76. 
Stimulation by exogenous ATP could also provide a putative mechanism for mast cell 
activation in skeletal muscle.  ATP can not only act as a DAMP released from necrotic fibers, but its 
endogenous release during contraction is said to potentiate contractile force by acting on purinergic 
receptors resulting in calcium influx77.  Exogenous release of ATP in this manner is also said to have 
autocrine effects resulting in increased glucose uptake and IL-6 expression78,79.  Interestingly, it was 
recently shown that the ATP-sensitive P2X7-receptors on mast cells mediate initiation and 
exacerbation of intestinal inflammation, which was also characterized by a neutrophil infiltrate80.  
Whether or not exogenous ATP could have these same effects on mast cells residing in skeletal 
muscle is not known, but it is an intriguing possibility.   
Even though the exact mechanism of mast cell activation in skeletal tissue remains elusive, it 
has been shown to be critical for the migration of short-lived neutrophils to the site of injured tissue.  
Indeed, inhibiting mast cell degranulation with the stabilizing agent sodium cromolate inhibited 
neutrophil infiltration into the skeletal muscle of rats by as much as 80% when challenged with 
bupivacain63.  Mast cells along with some granulocytes are also said to be one of the first sources of 
IL-4, which can convert resident macrophages into a wound healing subtype.  
2.2.2 Demolition tactics of the heavy-handed neutrophil 
Neutrophils are critical, yet destructive innate effectors whose principle role in wound healing 
is microbial sterilization.  These short-lived cells act as innate kamikazes in the battle against 
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infection, striking in as little as 15-45 minutes upon entry into damaged peripheral tissue.  That is 
unless they encounter a bacterium, at which time they tacitly decide their fate by either starving the 
bacterium of essential factors that they require, such as iron, or delivering a payload consisting of 
peroxidase positive and negative granules, activation of their nascent phagosome, and the final 
pouring out their cytosol.  They will even go as far as extruding their own chromatin in DNA nets 
laced with proteases from azurophil granules to vanquish their microbial prey.   
Mast cell mediated neutrophil infiltration from peripheral circulation into the effected tissue 
occurs within minutes to hours after insult and requires extravastion across local endothelial 
vasculature.  This occurs in four sequential steps involving selectin facilitated rolling, tight binding 
between leukocyte integrins and endothelium adhesion molecules, diapedesis via PECAM or CD31 
expressed on both the leukocyte and at the intercellular junctions of endothelial cells, and chemokine 
mediated migration81.  This general description of extravastion is followed by all exudate leukocytes, 
although the particular selectins, integrins, and adhesion molecules vary according to cell type.  
Neutrophils specifically require P- and L- selectin, integrin CD11b/CD18 (Mac-1), and intercellular 
adhesion molecule-1 (I-CAM, CD54).  Upregulation of P-selectin on endothelial cells can be 
stimulated by histamine, leukotriene C4 (LTC4), or oxidants and upregulation of CD11b/CD18 on 
neutrophils is activated by platelet activating factor (PAF) or LTB4, all of which can be generated by 
mast cells82,83.  L-selectin is constitutively expressed on circulatory neutrophils and in combination 
with P-selectin facilitates rolling along the endothelium, however it must be shed before tight binding 
between CD11b/CD18 and I-CAM can occur.  The neutrophil chemoattractant IL-8, also released 
from mast cells, has been shown to stimulate shedding of L-selectin84.  Another important and unique 
feature of mast cells is their ability to retain stores of endogenous TNF-a.  Mast cell degranulation 
and consequent release of TNF-a can in turn upregulate I-CAM, the ligand for CD11b/CD18 on the 
surface of vascular epithelium85.   
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High plasma catecholamine, growth hormone, and cortisol levels have been responsible for 
increasing granulocyte count by up to 250% in the 3 hours following a high-intensity, endurance 
event20,86.  If tissue damage occurs in exercising muscle during this time, activated neutrophils are 
certain to be a source of unrequited damage.  Indeed, induction of lengthening contractions in 
extensor digitorum longus (EDL) muscles of mice deficient in CD18, a prerequisite for neutrophil 
diapedesis, had significant reductions in carbonyl content, a marker of oxidative damage, and 
histological and functional signs of muscle injury compared to wild-type87  Despite their destructive 
potential, these cells are critical for staving off infection.  Without them, non-sterile wounds tend to 
heal poorly and can cause lethality as evidenced in patients with full-thickness burns or deficiencies 
in microbicidal machinery.  As key regulators in the inflammatory response, they are involved in 
recruitment, activation, and programming of antigen presenting cells (APCs) and serve as a source of 
chemokines attracting monocytes and dendritic cells (DCs) to the site of injury.  In addition, their 
influence on macrophage polarization from pro- to anti-inflammatory states may be of unequivocal 
importance in myofiber regeneration88,89.  However, the necessity for neutrophils in exercising muscle 
has yet to be shown and contraction injured CD18-/- mice retain macrophage recruitment comparable 
to wildtype, as well as faster restoration time of fiber size and force87. 
2.2.3 Macrophage polarization & facilitation of tissue repair 
Macrophages are among the most essential of all innate effectors.  They are the ‘garbage 
collectors’ of the body, clearing exogenous cellular waste from the interstium.  Impressively, they are 
responsible for the clearance of around 2x1011 erythrocytes per day, which would equate to 
‘recycling’ 3 kg of iron and haemoglobin per year.  As phagocytes, these cells carry out their day to 
day functions independent of other effectors of the immune system.  That is until the resident 
macrophage comes across debris indicative of the trauma or stress associated with DAMPs.  
Macrophages detect these endogenous danger signals via their toll-like receptors (TLRs), intracellular 
pattern recognition receptors, and the interleukin-1 receptor (IL-1R), most of which signal through the 
adapter protein myeloid differentiation primary-response gene 88 (MyD88).  With this cue they 
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change their repertoire of surface proteins as they gear up production of pro-inflammatory 
mediators90.  
Macrophages differentiate from peripheral blood monocytes upon their entry into tissue either 
in the steady state or at the on slot of inflammation.  Monocytes arise from myeloid progenitors in the 
bone marrow that diverge into various cell lineages, including neutrophils, eosinophils, basophils, 
macrophages, dendritic cells (DCs), and mast cells.  In order for monocytes to emerge from this 
progenitor pool, they must first differentiate into monoblasts followed by their pro-monocyte 
precursors, only achieving monocyte status upon joining the rush of peripheral circulation.  Although 
originating from the same precursors, not all monocytes are created equal and can extravasate at 
different stages of maturity, which may play a role in determining their functional phenotype within 
tissue.  Murine monocytes at either end of this age continuum are termed ‘inflammatory’ and 
‘resident,’ with the former spending the least amount of time in the bloodstream.  Furthermore, these 
fairly evenly distributed populations can be identified according to the expression of particular cell 
surface markers.  CCR2+ (CC-chemokine receptor 2), CX3CR1low, Ly6+ (also known as GR1) is said 
to designate an inflammatory monocyte and CCR2-CX3CR1highLy6- a resident monocyte91.  In 
humans, these designations are CD14highCD16- and CD14+CD16+ and are referred to as ‘classical’ and 
‘non-classical,’ respectively92.  It is interesting to note that in humans, the distribution of these 
populations is far from even, with the ‘classical’ monocytes making up approximately 90%92.  So-
called ‘inflammatory’ monocytes can further differentiate into either resident macrophages or DCs, 
while ‘resident’ monocytes continue to navigate the vasculature until an incidence of inflammation or 
trauma91. 
In mouse skeletal muscle, residential macrophages have been identified as 
CD11b+F4/80+CD11c-Ly-6C-CX3CR1-41.  In a homeostatic state these cells occupy the epimysium 
and perimysium connective tissue that sheath entire muscles and their fasciles, respectively.  Upon 
recognition of tissue injury, they selectively release cytokine induced neutrophil chemoattractant 
(CINC or human IL-8) and monocyte chemoattractant protein 1(MCP-1 or CCL2).  IL-8 is a ligand 
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for either CXCR1 or CXCR2 on neutrophils, basophils, CD8+ T-cells, and endothelial cells.  MCP-1 
or CCL2 is a ligand for CCR2 on monocytes, T cells, basophils, immature dendritic cells, and natural 
killer (NK) cells.  Upon stimulation by TNF-a, endothelial cells can also secrete these two 
chemokines, resulting in the appearance of monocyte infiltration at 8 hours post injury, in addition to 
continued neutrophil and mast cell recruitment.  After 24 hours, macrophages are the predominating 
immune cell in the affected tissue and persist for days. 
 Tissue macrophages derived from circulating CCR2+ monocytes are said to exist in a 
spectrum of phenotypes.  M1 and M2 describe the extreme polarization of these phenotypes and have 
pro- or anti-inflammatory roles, respectively.  More specifically, the M1 phenotype is characterized 
by the expression of inducible nitric oxide synthase (iNOS) and pro-inflammatory cytokines such as 
TNF-α, IL-1β, and IL-6.  IL-1β released by these macrophages will in turn stimulate parenchymal 
cells to release CXCL1 and CXCL2, chemokines that recruit more neutrophils to the affected muscle 
tissue93. The M2 phenotype has a far more diverse characterization, including expression of arginase-
1, CD163 and mannose receptor, and/or anti-inflammatory cytokines such as IL-10.  Macrophages 
derived from ‘resident’ monocytes have many important functions in resident tissues that include, 
phagocytosis of material (antigen, bacteria, injured or apoptotic cells), antigen presentation, secretion 
of pathogen fighting enzymes and oxidative derivatives, and production of growth factors and 
cytokines that influence parenchymal tissue, and immune cell recruitment. 
2.2.4 Recently discovered roles for leukocytes in muscle regeneration 
 The role of immune cell infiltration into skeletal muscle is not limited to the production and 
resolution of inflammation for the removal of cellular debris.  Indeed, regulation of stem and 
progenitor cells that either repair or replace damaged skeletal muscle tissue is dependent on this 
infiltrate.  Until recently, mechanisms delineating exactly how this might occur were relatively 
unknown.  In 2013, researchers out of University of California, San Francisco published a study 
describing an essential role for IL-4 and IL-13 signaling in muscle regeneration.  They were able to 
show that upon cardiotoxin (CTX) induced injury, IL-4/IL13-/- mice developed persistent 
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inflammatory infiltrates and cellular debris in tibialis anterior (TA) muscle.  Furthermore, the efficacy 
of the regenerative response in the skeletal muscle of these mice was impaired as evidenced by their 
significant relative uptake of Evans blue dye, which accumulates in damaged muscle fibers.  In 
addition, histological examination of CTX injured TA muscles from IL-4/IL13-/- mice revealed a 
failure to regenerate centrally nucleated fibers compared to wildtype (WT).  Immunostaining for 
desmin, a marker of mature myofibers, also confirmed an absence of regenerated muscle fibers in.  To 
identify the source of IL-4 production in regenerating muscle, they utilized 4get reporter mice, which 
express green fluorescent protein (GFP) from the 3’ untranslated region (UTR) of the endogenous IL4 
gene.  Using flow cytometry, they were able to gate on these GFP+ cells from injured muscle and 
noted that ~85-90% of these cell expressed markers indicative of eosinophils (Siglec F+CD11b+).  
Surprisingly, these results suggest that eosinophil and not myeloid derived type 2 cytokine signaling 
is required for the timely and complete regeneration of skeletal tissue94. 
 Researchers out of Harvard University in Boston have also established a role for regulatory T 
(Treg) cells in potentiating skeletal muscle repair.  They were able to punctually delete Tregs from 
skeletal muscle following CTX injury by utilizing a mouse line in which the diphtheria toxin receptor 
(DTR) was expressed under the control of forkhead box p3 (Foxp3) regulatory elements.  Thus, upon 
diphtheria toxin (DT) injection, B6.Foxp3-DTR+ mice experienced specific deletion of Foxp3+CD4+ 
cells, markers that identify Tregs.  When these B6.Foxp3-DTR+ mice received DT either 
intraperitoneally or intramuscularly at the time of CTX injection, there was a larger CD45+ cellular 
infiltrate into skeletal muscle compared to DTR- mice, and myeloid cells within this infiltrate failed 
to transition between a primarily pro-inflammatory, Ly6chi to an anti-inflammatory Ly6clo phenotype.  
In addition, histological examination showed that there was a disorganized pattern of centrally 
nucleated fibers indicative of regeneration and Gomori’s Trichrome staining revealed a substantive 
accumulation collagen indicative of fibrosis95. 
2.3 NF-kB: Master Regulator of Inflammation in Skeletal Muscle 
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 In a matter of hours following injury, skeletal muscle accumulates both fluids and leukocytes 
from peripheral circulation, including neutrophils, eosinophils, and monocytes.  Monocytes 
extravasating into inflammed tissue are immediately programmed into M1 macrophages, secreting a 
host of cytokines in a paracrine and autocrine manner, including TNF-α, IL-1β, and IL-6.  These pro-
inflammatory cytokines are all regulated at least in part by the transcription factor nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) in macrophages96.  TLR signaling is one of 
the most well-known ways of activating the intercellular signaling pathway that leads to NF-κB 
activation.  Indeed, it is common to find in vitro assays assessing anti-inflammatory potential utilizing 
TLR ligands, such as lipopolysaccharide (LPS), to initiate NF-κB signaling.  Section 2.3 will cover 
NF-κB signaling and its occurrence in both macrophages and myocytes where relevant. 
2.3.1 Canonical and non-canonical NF-κB signaling pathways 
 Inducible NF-κB has been detected in virtually every cell type and is highly conserved among 
species.  Mammalian NF-κB exists as either hetero- or homo- dimers composed of the proteins, 
RelA/p65, RelB, c-Rel, NF-κB1/p50, and NF-κB2/p52, the last two of which are derived from the 
precursor subunits p100, and p105 97.  These proteins have the same 300-amino acid sequence termed 
the Rel homology domain (RHD), which is responsible for DNA binding, subunit dimerization, 
nuclear translocation, and physical interaction with any one of seven ankyrin repeat-containing 
inhibitors called IκB proteins.  NF-κB predominately acts to promote transcription of its target genes, 
with transcriptional repression only occurring with p50/p50 and p52/p52 complexes98.  
 There are two functional pathways in which NF-κB can undergo rapid activation and nuclear 
translocation, termed canonical and non-canonical.  The former can be activated by a myriad of 
exogenous and endogenous factors, including ROS, growth factors, pro-inflammatory cytokines, 
genotoxic stress, viruses, and bacterial polysaccharides.  Even in their inactive state, hetero- and 
homodimers of NF-κB can actively shuttle between cytosol and nucleus due to an exposed nuclear 
localization signal (NLS) on p50, which is not effectively masked by IκB protein99.  Upon cell 
stimulation by any one of the aforementioned factors, activation of inhibitor of kappa B kinase (IKK) 
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will occur, which is made up of three subunits, IKKα and IKKβ, which are necessary for kinase 
activity, and IKKγ (NEMO), which serves as a regulatory protein97.  Specifically, IKKβ of this 
complex functions to unmask the nuclear localization signal (NLS) on p65 by phosphorylating two 
amino-terminal serine residues (ser 32 and serine 36) on IκB, resulting in its polyubiquitination by an 
SCF family ubiquitin ligase and subsequent degradation by the 26S proteasome.  This will permit p65 
and p50 heterodimers to translocate into the nucleus where they bind to promoter and enhancer sites 
containing κB consensus sequence, GGGRNNYYCC, where R is a purine, Y is a pyrimidine, and N 
is any base100.  Blocking this pathway in mice causes non-specific responses to infection and 
functional impairment in B-cells, and thus ascribes vital roles both innate and adaptive immunity101. 
 In contrast to the canonical pathway, which has been found ubiquitously in most mammalian 
cell types, the non-canonical pathway is an alternative means of NF-κB activation found only in B-
cells and is responsive to members of the TNF-receptor (TNFR) superfamily important in B-cell 
maturation and lymphoid organogenesis, including B-cell activator (BAFF), lymphotoxin-β (LTβ), 
CD27, and CD40 ligand102–106.  When these ligands interact with their respective receptors on the 
surface of B-cells, it induces activation of an intracellular downstream kinase called NF-κB inducing 
kinase (NIK).  This kinase will preferentially phosphorylate IKKα, which in turn will phosphorylate 
serine residues 866 and 870 on p100, leading to its polyubiquitination at Lys-855 and partial 
degradation into p52 by SCFβTrCP E3 ligase complex107.  In its resting state, p100 is sequestered in the 
cytoplasm by the RelB subunit of NF-κB.  However once processed, the newly formed p52 and RelB 
dimer undergoes nuclear translocation to regulate distinct target genes from the canonical pathway.  
Transgenic mice lacking the non-canonical form of NF-κB have severe functional defects in their B-
cells and impaired formation of peripheral lymphoid organs108,109. 
2.3.2 Redox sensitive activation of NF-kB 
 It has been known for well over a decade that intracellular signaling that leads to transient 
NF-κB activation can be regulated by redox status in a cell type specific manner110–119.  In fact, one of 
the first known exogenous activators of NF-κB was H2O2 in the early 1990s120.  It is now known that 
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effective stimulation by either lipopolysaccharide (LPS) or proinflammatory cytokines like TNF-α 
and IL-1β not only require ROS, but also lead to enhanced production of ROS by concurrent 
activation of Rac1-NADPH oxidase complexes121–123.  To this effect, decreases in intracellular GSH 
to GSSG ratio have been shown to correlate with increased IκBα phosphorylation and subsequent NF-
κB activation124,125, while antioxidants such as glutathione peroxidase126 and N-acetyl-cysteine 
(NAC)127,128 are known to effectively inhibit this pathway. 
 Cytoplasmic kinases in the NF-κB signaling pathway that are said to be redox sensitive 
include, IKK, mitogen-activated protein kinase/ERK kinase-1 (MEKK-1), and phosphoinositide 3-
kinase (PI3K)/Akt117.  MEKK-1 can potentiate stimulatory effects of either TNF-α or IL-1β on the 
canonical NF-κB pathway by directly interacting with IKKβ to mediate its site-specific 
phosphorylation129,130.  Akt is a serine/threonine kinase with an inherent role in cell survival.  It can 
also be activated by cytokines TNF-α and IL-1β, as well as LPS, following its recruitment to the 
cellular membrane in response to 3’phodphotylsyrf phosphoinositides generated by PI3K131.  In a 
similar fashion to MEKK-1, Akt activation can lead to transactivation of IKKβ, but only in cells with 
a higher ratio of IKKα to IKKβ132.  Furthermore, Akt may not be relevant in exercise-induced NK-κB 
activation since overexpression of MEKK-1, but not Akt, in a line of mouse myoblasts (C2C12) was 
able to potentiate DNA-NF-κB binding activity133.   
 Oxidant status can not only affect NF-κB’s translocation into the nucleus by redox regulation 
of cytoplasmic kinases, but can also directly impact NF-κB transcriptional activity within the nucleus.  
Redox sensitive proteins implicated in this manner of NF-κB regulation include protein kinase C ζ 
(PKCζ), cAMP-dependent protein kinase (PKA), mitogen and stress activated kinase-1 (MSK-1), 
ribosomal S6 kinase-1 (RSK-1), and casein kinase 2 (CK-2)117.  However, NF-κB binding activity in 
the nucleus requires reduced conditions compared to oxidant-induced activation of pertinent cytosolic 
kinases. 
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2.3.3 NF-κB activation during exercise 
 Goodyear et al. (1996) first described a link between exercise and activation of redox-
sensitive signaling pathways important to antioxidant gene expression.  Results from this study 
described increased activation of JNK, ERK1/2, and p38 after treadmill running (20m/min, 10% 
grade) for up to 60 minutes in rats134.  A year following this study, Sen et al. (1997) linked H2O2 
treatment to the potent induction of NF-κB signaling in L6 muscle cells, results of which 
corresponded with intracellular GSH:GSSG status135.  Similar levels of NF-κB binding were 
confirmed in rats after an exhaustive bout of exercise in rats.  This study reported relative levels of 
NF-κB binding in both deep vastus lateralis (DVL, type IIa) and superficial vastus lateralis (SVL, type 
IIb) since important changes in metabolic and antioxidant function have been described in this muscle 
group during endurance exercise.  Their results indicated that significant binding of NF-κB occurred 
in respective muscle types, peaking at 2 hours post-exercise and attributed transient activation of this 
transcription factor to the generation of ROS 136.  This same group would later go on to show both the 
activation and time course of other important members of the NF-κB signaling cascade as well, 
reporting significantly higher levels of p50 protein content, phosphorylated IκBα, and IKK in rats run 
for one hour or until exhaustion (25 m/min, 5% grade) compared to control.  Peak activation of 
IKKα/β occurred within 15 minutes of exercise and IκBα phosphorylation remained elevated up until 
the immediate hour following exercise, with levels of p65 reaching their peak 2-4 hours post-exercise.  
These effects were significantly abolished by pyorrlidine dithiocarbamate treatment, a potent inhibitor 
of the 26S proteasome, and mimicked in a group of sedentary controls receiving lipopolysaccharide 
(LPS) prior to sacrifice 137.  Also, inhibiting either extracellular-signal regulated protein kinase (ERK) 
or p38 kinase effectively blunted contraction mediated IKK phosphorylation, especially when 
combined at 76 ± 5%138. 
 Redox status can have a number of effects on transcriptional activity, many of which are 
species or tissue specific.  It is hard to say how many genes are influenced by homeostatic regulation 
of muscle oxidation-antioxidant balance.  Roles for NF-κB transcriptional regulation to this affect are 
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still putative and include upregulation of antioxidant genes to counter oxidative stress, pro-
inflammatory genes critical for muscle regeneration following exercise, and genes important in 
cellular metabolism, including glucose transport, glycogen repletion, and lipid oxidation139. 
2.3.4 NF-kB regulation of endogenous antioxidant expression 
 Several important antioxidant enzymes are under at least partial transcriptional regulation by 
NF-κB in skeletal muscle, two of the most essential include mitochondrial superoxide dismutase 
(MnSOD) and glutathione peroxidase (GPX)110,139.  MnSOD serves as the first line of defense against 
mitochondria derived ROS since it is responsible for converting superoxide radicals, escaping from 
complex I and III of the electron transport chain, to hydrogen peroxide (H2O2) and oxygen (O2).  
There are three isoforms of SOD, 15-35% of which is active in the mitochondria and 65-85% 
remaining in the cytosol140,141.  Evidence that this enzyme is actively upregulated by NF-κB during 
endurance training has been demonstrated in rats 48 hours post-exercise in type IIa, type I, and mixed 
type II by 80%, 54%, and 42%, respectively142.  Type IIa and I muscle fibers in mice also exhibit 
higher levels of mitochondrial mass relative to mixed type II or IIb fibers143.  In a subsequent study, 
observed increases in the transcription of MnSOD mRNA were only found in type IIa and not in type 
IIb immediately following exercise136.  Increased expression of MnSOD has also been reported in 
human skeletal muscle both following acute submaximal exercise and 4 weeks of endurance 
training144,145. 
 Expression of GPX is regulated both by NF-κB and AP-1, and of the 5 isoforms that exist in 
humans GPX1 and 3 appear to be functional in skeletal muscle110,141.  These enzymes utilize GSH as 
an electron donor for reduction of either H2O2 or organic hydroperoxide (ROOH) into water (H2O) 
and alcohol (ROH), respectively146–148.  Similarly to SOD, active GPX has been found to be more 
prevalent in fiber types with high oxidative capacity that are recruited during submaximal endurance 
exercise.  In fact, it has been reported that GPX activity can increase in response to endurance 
training, which can range from 20-177%149.  By transfecting C2C12 cells with a trans-dominant 
inhibitor of IκBα, Zhou et al. 150 showed that GPX gene expression was inhibited by approximately 
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80% in response to H2O2.  If these results can be extrapolated to human myocytes, then active NF-κB 
regulation of this enzyme would be essential in the upregulation of this essential, endogenous 
antioxidant enzyme. 
2.3.5 NF-kB induction of pro-inflammatory factors 
  Canonical activation of NF-kB can induce transcription of a host of pro-inflammatory genes, 
such as interleukin (IL)-1, IL-2, IL-6, and TNF-α, as well as chemokines such as IL-8, macrophage 
inflammatory protein (MIP)-1α, monocyte chemotactic protein-1 (MCP1), regulated upon activation 
normal T-cell expressed and secreted (RANTES, CCL5), and eotaxin. Additionally, it can upregulate 
adhesion molecules essential to the propagation of the inflammatory response, including the 
intercellular adhesion molecule (ICAM), vascular cell adhesion molecule (VCAM)-1, and E-
selection, along with inducible enzymes such as COX-2 and iNOS, growth factors, some acute phase 
proteins, and immune receptors151.  Sustained exercise is also known to induce expression of IL-8, 
and anti-inflammatory IL-10 and IL-1ra in circulating blood leukocytes4,152,153.  To a degree, 
upregulation of these various factors is essential to facilitate post-exercise regenerative responses in 
damaged tissue and hypertrophic adaptations154. 
2.4 Prospective Use of Flavonoids to Improve Athletic Performance 
 The physiological effects of flavonoids as secondary, plant metabolites in humans have been 
of peak interest in the scientific community due to their putative antioxidant, antiviral, 
immunomodulatory, antithrombotic, antimicrobial, and anticancer action155–160.  Interestingly, it 
wasn’t until the early 1980s that the pharmacological potency of this phytochemical group was 
recognized, despite the fact that preparations of flavonoids had been used by laymen and physicians 
to treat human diseases for centuries prior to that time6.  Since then, there has been increasing interest 
in the beneficial effects of polyphenols on human health and performance by both researchers and 
food manufacturers. 
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2.4.1 Classification and chemistry of quercetin and epigallocatechin gallate (EGCG) 
Flavonoids, a major class of polyphenols, are distinguished by a fifteen carbon 
phenylchromane core made up of two aromatic rings, designated A and B, bound together by an 
oxygenated heterocycle, ring C.  Flavonoid subclasses are differentiated according to their respective 
heterocycle, with numerous members making up each subclass due to the varying degree in which A 
and B rings are hydroxylated or methoxylated161,162.  Quercetin and epigallocatechin gallate (EGCG) 
belong to the flavonol and flavanol subclasses, respectively.   
Quercetin is present in plants in several different glycosidic forms, the most common of 
which is quercetin-3-rutinoside, also called quercetin-3-rhamnoglucoside or rutin.  In onions, 
quercetin is bound to one or two sugar moieties, D-glucose or L-rhamnose, at the C-3 or C-7 position 
(quercetin-4’glucoside and quercetin-3,4’glucoside)163.  In contrast, flavanols, including EGCG, are 
the only subclass of flavonoids that do not form a glycoside in plants and are extremely stable even 
upon exposure to boiling temperatures for 7 hours as long as pH does not rise above 6.5164. 
2.4.2 Occurrence of quercetin and EGCG in the human diet 
 Flavonoids are abundant micronutrients in the human diet with over 6000 identified in 
plants165.  Fruits and beverages such as teas and wine are the predominant source of most 
polyphenols, with flavonols making up the most ubiquitous subclass at concentrations of ≈15-30 
mg/kg fresh weight, found most commonly in onions (1.2g/kg fresh wt.), kale, leeks, broccoli, and 
blueberries.  In the United States, the estimated intake of flavonols and flavones among health 
professionals was 20 to 22 mg/day in 2002, of which 73% and 76% was quercetin in men and 
women, respectively166.  Dietary sources of quercetin are commonly tea, red wine, fruits, and 
vegetables167,168.  Functional foods made up of 0.008-0.5% or 10-125 mg/serving of quercetin have 
been used as nutraceuticals. 
 Attempting to get recommended nutraceutical doses of particular flavonoids from diet alone 
remains a challenge due to many factors affecting polyphenol content in foods, such as ripeness at the 
time of harvest, environmental factors, processing, storage, and culinary preparation161.  Biosynthesis 
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of flavonols in plants is directly stimulated by light, which is why they are typically localized in the 
outer and aerial tissues.  Accordingly, concentrations of quercetin can vary from plant to plant or even 
throughout a single piece of fruit based on exposure to sunlight169.  Other environmental effects that 
can influence polyphenol content include other pedoclimatic factors, such as soil type and rainfall, 
and agronomic factors, such as being planted in a greenhouse versus a field, biological and 
hydroponic culture, and fruit yield per tree.  The most significant loss of polyphenol content likely 
occurs during culinary preparation.  Since most polyphenols are located in the skins or outer portions 
of fruits and vegetables, simply peeling these foods could eliminate them from a meal.  Cooking can 
also have a significant impact on flavonoid content.  After boiling tomatoes or onions for 
approximately 15 minutes there is a marked reduction in quercetin content anywhere from 75 to 80%, 
65% after microwaving, and 30% after frying170.  Fortunately, quercetin is also available as a dietary 
supplement in many countries including the US at a recommended dosage range of 200-1200 
mg/day171.  All toxicity data to date on quercetin’s use in either respect support its safety in 
humans171,172. 
2.4.3 In vivo fate of quercetin and EGCG 
 Before discussing the therapeutic potential of either quercetin or EGCG in humans it is 
important to know their in vivo fate.  Bioavailability of both the aglycone form of quercetin and the 
plant-based glycoside will be addressed to note any differences between obtaining this flavonoid from 
functional foods versus supplementation. 
 In general, polyphenols are metabolized via a common pathway173.  Hydrophilic glycosides 
are hydrolyzed at the brush border of the intestines by intestinal enzymes or colonic microflora.  
Efficiency of absorption is significantly lower when bacteria are involved because subsequent 
aglycones are typically further degraded into simple aromatic acids.  Aglycones that withstand 
degradation undergo conjugation involving methylation, sulfation, and glucuronidation both in the 
small intestine and the liver after transport via the hepatic portal vein.  The metabolic processes 
associated with the conjugation of flavonoids are otherwise known to decrease the toxic and 
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biological effects of compounds like xenobiotics, as well as increasing the hydrophilicity required for 
their biliary and urinary excretion161. 
 Initially it was thought that intestinal absorption of quercetin glycosides could only occur 
after hydrolytic enzymes from colonic microflora released the aglycone174,175.  This was a reasonable 
assumption since intermembrane transport proteins specific for flavonoids had yet to be identified, 
and according to the rule-of-five prediction model, hydrophilic compounds with a molecular mass 
greater than 500 are incapable of passive diffusion across enterocytes176.  Additionally, after 
administering 4 grams of quercetin to 6 volunteers Gugler et al. (1975) failed to detect it in either 
plasma or urine177.  Quercetin glycosides are now known to be absorbed in the small intestine after 
hydrolysis by either brush border enzymes, such as lactase phloridzin hydrolase and cytosolic β-
glucosidase, or colonic microflora178–180.  If, however, quercetin is ingested in its aglycone form then 
it can also to some extent undergo absorption flux from the gastric wall of the stomach.  When a 15 
µmol/L concentration of quercetin was injected into the gastric lumen of rats, only 62% of that 
administered dose was recovered in the gastric content, with absorptive flux by the gastric wall 
reported at 1.11±0.08 nmol/min181.  Flavanols, such as EGCG, are also present in plants solely in an 
aglycone form (without a sugar moiety), however depolymerization has not been reported within the 
stomach.  In fact, when six healthy, human subjects were allowed to drink a flavanol rich cocoa 
beverage no change was observed in the HPLC profile of procyanidins, oligomeric compounds 
formed from catechins and epicatechin molecules182. 
 Intestinal uptake and subsequent biliary excretion of quercetin glycosides varies according to 
their respective sugar moiety, but not the position at which it is attached to the quercetin molecule.  
Following a 30-minute in situ intestinal perfusion in rats, quercetin-3-O-glucoside and quercetin-4’O-
β-glucoside were readily absorbed and corresponding peripheral plasma and portal vein metabolites 
recovered.  However, when the same experiment was run with quercetin-3-O-β-galactoside, 
quercetin-3-O-rhamnoside, and quercetin-3-O-α-arabinopyranoside they were resistant to hydrolysis 
and only trace amounts of metabolites were detected183.  Quercetin glucosides are also absorbed more 
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readily then the aglycone form of quercetin when taken orally.  When nine healthy ileostomy subjects 
were given diets of either fried onion made up predominantly of glucosides, quercetin rutinoside, or 
quercetin aglycone, absorption defined as oral intake minus ileostomy excretion, was 52±14%, 
17±15%, and 24±9%, respectively184.  
 The most common way EGCG is administered in human clinical trials is within green tea or 
green tea extract, which also contains other active catechins, including epigallocatechin (EGC) and 
epicatechin (EC).  Despite similarity in chemical structure, these catechins display differing 
pharmacokinetics, with EGCG displaying the poorest bioavailability.  When green tea was 
administered in three repeated experiments to eight human subjects, plasma concentrations of EGCG, 
EGC, and EC were 77.9±22.2, 223.4±35.2, and 124.03±7.86 ng/ml, respectively185.  Interestingly, 
Zhu et al (1997) looked at the effect of pH on the stability of these catechins since there is a rapid 
change in pH from the stomach to the intestine and found that EGCG was preferentially destroyed in 
solutions with pHs over 6.5, while EC and ECG were relatively stable164.  The low bioavailability of 
EGCG is significant in terms of its potential therapeutic use since most published cell culture studies 
use concentrations of EGCG in the 10-100 µM range at pH 7.4186. 
 The relative importance of conjugation, be it methylation, sulfation, or glucuronidation, 
appears to be dependent on the type of substrate (aglycone or type of glycoside) and the dose 
ingested.  Typically, when quercetin is ingested as a nutraceutical in functional foods, conjugation of 
the aglycone after hydrolysis in the small intestine will occur immediately by small intestinal 
microsomes in the -3-, -7-, -4’- and -3’-position187.  However, if the concentration of aglycone is high 
enough, as can be the case with pharmaceutical doses, conjugating enzymes in the small intestine 
become saturated and free (unconjugated) quercetin will pass into the hepatic portal vein in route to 
the liver.  The principle conjugates leaving the small intestine are quercetin-7-glucuronide and 
quercetin-3-gluronide.  If incubated with HepG2 cells, used as an in vitro hepatic model system, 
quercetin-7-glucuronide was metabolized by either methylation in the 4’- and 3’-position (catechol 
moiety) or deglucuronidation by β-glucuronidase followed by sulfation.  A similar metabolism profile 
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can also be said for quercetin-3-glucuronide with methylation and sulfation accounting for 32% and 
10.2% of quercetin in media after 48 hours, respectively.  In contrast, quercetin aglycone yielded four 
classes of metabolites that were qualitatively similar to those from quercetin-3- and quercetin-7-
glucuronides, but the rate of metabolism occurred faster over a 24-hour period188.  The same 
metabolites for this study have also been reported in rats, rat hepatocytes, and human plasma189–191.  
Interestingly, EGCG is one of the few flavonoids that predominantly escapes conjugation in the liver 
and small intestine and instead can be found in free (unconjugated) form in human plasma hours after 
ingestion185,192. 
 Following absorption in the small intestine and metabolism in the liver, bioavailability of 
flavonoid metabolites in peripheral tissues is dependent on both their binding within plasma and their 
elimination route from the body.  From the liver, quercetin conjugates have an extremely high affinity 
(>99%) for the plasma protein albumin in systemic circulation, which may result in poor tissue 
deposition193.  Alternatively, it may however delay the clearance of quercetin metabolites from the 
body, providing a way station, so to speak, for their distribution to target organs194.  Significantly, 
elimination of quercetin metabolites in humans is quite slow, with half-lives ranging from 11 to 28 
hours195.  Methylated and/or sulftated and/or glucuronidated metabolites are polar, water-soluble 
compounds and thus can be excreted via either bile or urine.  How the particular metabolite is 
conjugated does influence the elimination pathway, with glucuronides secreted in bile to a higher 
degree then sulfates, which are typically eliminated via urine196.  If metabolites are secreted in bile 
then they end up in the duodenum, where they are further hydrolyzed by bacteria in the large 
intestine.  The resultant products may be reabsorbed back into the body and undergo enterohepatic 
cycling197.  Compared to the relatively slow elimination of quercetin metabolites, catechins such as 
EGCG have relatively fast-half lives195. 
 The metabolic fates of quercetin could also differ between humans and mice.  Indeed, a study 
measuring quercetin in both human and mouse plasma found that a large proportion of quercetin was 
methylated to isorhamnetin (up to 48%), while only low amounts of isorhamnetin could be detected 
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in the human plasma samples.  The general conclusion from this data was that differences in the 
hepatic conversion of quercetin into its methylated metabolite isorhamnetin might differ between 
mouse and human.  However, it is also possible that the quercetin dose was responsible for this effect, 
since the dietary quercetin concentrations used in the study (0.05-2mg/g diet) corresponded to 10-400 
mg quercetin per kg body weight, which is several times higher than quercetin concentrations that can 
be achieved in humans198.  An even more dramatic difference in flavonoid metabolism between 
species has been described for EGCG.  In mice, it has been reported that 50-90% of EGCG present in 
plasma was conjugated, which differs from results reports in humans in which plasma EGCG was 
largely unconjugated185,192,199.  
2.5 Quercetin’s Effect on Inflammatory Response: in vitro studies 
Quercetin is among one of the most highly investigated flavonoids for its potential use as a 
performance enhancing nutraceutical.  The most obvious reason to link quercetin supplementation 
with improved athletic performance is its ability to scavenge oxidizing species created during intense 
and prolonged exercise.  In fact, many flavonoids, particularly those containing a catechol structure 
on their B-ring (3’4’dihydroxyl), have proven to be efficient antioxidants200,201.  As will be evident 
later in this review, there are numerous in vitro and in vivo studies that provide convincing evidence 
of putative therapeutic benefit.  Epidemiological data also lends support to the idea that a quercetin 
rich diet aids in disease prevention, including reduced risk of colorectal, kidney, pancreatic, prostate, 
lung, and breast cancer, cardiovascular disease, and diabetes mellitus202–211.  
 Early studies looking at the effect of quercetin on macrophage function date back to the late 
1990s.  At this time, the plasticity and functional polarization of tissue macrophages was just 
beginning to be appreciated, with the concept of M1, M2a, M2b, and M2c polarization not being 
formally established until 2004212.  Early in vitro study design typically utilized the commercial 
murine RAW 264.7 or J774A.1 monocyte cell line, which could be further differentiated into what 
was termed classical macrophages upon stimulation with LPS or cytokines such as INF-g or TNF.  
Today we would recognize this type of activation as geared towards an M1 macrophage fate213.  Two 
   
 
 
26 
studies published in 1999 utilized this method to make the seminal finding that incubation with 
quercetin at concentrations ranging from 50-200 µM was able to significantly inhibit TNF-a and 
nitric oxide (NO) secretion from these cells214,215. 
The finding that quercetin can inhibit nitric oxide production in murine macrophages has 
been described in numerous studies214,216–227.  However, quercetin’s capacity to inhibit TLR mediated 
inducible nitric oxide production is in itself not relevant in humans.  Both mice and human 
macrophages are capable of TLR2 activation and subsequent antimicrobial response, but iNOS 
inhibitors L-NIL and L-NAME can only ablate this activity in mice, not humans.228  Instead, TLR 
signaling in human macrophages up-regulates expression of both the vitamin D receptor and vitamin 
D-1-hydroxylase genes, which in turn leads to the induction of the antimicrobial peptide 
cathelicidin229. 
Many studies reporting quercetin’s potent anti-inflammatory potential in macrophages cite its 
effect on prostaglandin E2 (PGE2) and a quintessential enzyme involved in PGE2’s production, 
cyclooxygenase-2 (COX-2)217–221,225,230–232.  COX-2 is an enzyme capable of converting arachidonic 
acid sequestered in the plasma membrane to prostaglandin H2. (PGH2), which is in turn converted to 
one of four types of prostanoids, including PGE2, by various terminal synthases233.  Starting in 2001, 
studies have reported quercetin’s effect on COX-2 expression in macrophages stimulated with LPS in 
vitro, but this effect was only significant at or above concentrations of 50µM217,218,225.  Achieving 
such a concentration of quercetin in human plasma is likely unrealistic, with the highest reported 
average to date at 20.97µM234.  Quercetin’s ability to inhibit PGE2 production is however far more 
impressive, with as little as 0.5µM required to significantly decrease expression LPS stimulated 
J774A.1 macrophages217.  The disparity in quercetin’s effect on PGE2 compared to COX-2 expression 
is important to note in the context of skeletal muscle.  During exercise, induction of prostaglandin 
expression is normal and positively correlates with exercise intensity235.  COX-2-/- mice are reported 
to have an impaired response to stretch, which normally stimulates myoblast production of PGE2, 
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PGF2a, and 6-keto-PGF1a contributing to vasodilation and hyperaemia in skeletal muscle236–239.  
Following injury these effects are exacerbated in NSAID treated or COX-2-/- mice to the extent of 
delayed muscle regeneration, due to a reduced capacity for myoblast proliferation, differentiation, and 
fusion240–242.  On the other hand, excessive levels of PGE2 in skeletal muscle have been linked to 
inflammatory myopathies243–247.  For instance, levels of dietary, saturated fatty acids, such as that 
found in patients with type 2 diabetes mellitus, have been linked to inflammation potentiated by 
excessive levels of PGE2 in skeletal muscle248.  The point at which PGE2 stops being solely beneficial 
to muscle recovery and begins to exacerbate an ongoing inflammatory response in muscle is 
unknown, but it is certainly possible that it could occur during intense and prolonged exercise.  In that 
case, a supplementing agent that can dampen PGE2 expression without effecting basal prostanoid 
production could have a positive impact on muscle performance and recovery. 
To date, the majority of macrophage studies reporting quercetin’s anti-inflammatory potential 
have looked at its influence on NF-kB activation and downstream regulation of pro-inflammatory 
gene expression.  As discussed previously, the NF-kB heterodimer RelA (p65) and p50 subunits are 
activated in the canonical signaling pathway following inflammatory stimulus from bacterial antigen 
and/or pro-inflammatory cytokines, such as LPS and TNF-a.  Once this signaling pathway is active in 
macrophages, the p65/p50 NF-kB heterodimer translocates to the nucleus where it regulates 
expression of a host of different genes, including many that are essential to the development and/or 
persistence of an inflammatory response.  Cytokine data from LPS stimulated macrophage cultures 
was the first and most reproduced evidence that quercetin could have an inhibitory effect on canonical 
NF-kB signaling.  Under these conditions, pretreatment with 3 up to 100 µM quercetin has been 
reported to significantly decrease transcription of TNF-a, while anywhere from 1 to 50 µM was been 
reported to significantly decrease TNF-a secretion214,220,222,223,227,249–253,253,254.  Similar findings have 
also been made for IL-1b, with 3 to 100 µM quercetin sufficient to inhibit transcription and 5 to 10 
µM quercetin significantly inhibiting protein secretion220,222,227,249,254.  Other factors under NF-kB 
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regulation that quercetin is reported to inhibit include CXCL10, IL-6, IL-8, and CCL3220,227,249.  The 
variance in quercetin concentration required to block cytokine expression in these studies is important 
to note, and can likely be explained by differences in experimental design. 
In order to define the mechanism through which quercetin inhibits TNF-a and Il-1b 
production in macrophages, several studies have investigated whether or not it has a direct effect on 
canonical NF-kB signaling.  The most convincing and reproducible evidence to support quercetin’s 
specific action on this pathway lies in its ability to inhibit LPS induced phosphorylation and 
subsequent degradation of the NF-kB inhibitory protein IkBα222,223,249,250.  IkBα partially masks the 
nuclear localization sequence of NF-kb and it itself contains a nuclear export sequence that can 
rapidly translocate the transcription factor out of the nucleus97.  Few studies have looked upstream of 
the transcription factor itself to determine where exactly quercetin may be inhibiting canonical 
signaling.  However, a comprehensive study published in 2013 was able to show that 20 µM 
quercetin was sufficient to inhibit degradation of TRAF-6 and reduce downstream phosphorylation of 
TAK-1 and IKKa/b.  In addition, Endale et al. proposed that quercetin exerts its inhibitory effects on 
NF-kB signaling through modulation of PI3 kinase activation resulting from the inhibition of tyrosine 
kinase Syc255.  However, the relevance of Syc and PI3 kinase in LPS activated TLR4 signaling 
remains a matter of debate256–260. 
2.6 Quercetin’s Effect on the inflammatory response: in vivo studies 
 Animals models have proven to be a useful tool in understanding the effect of quercetin 
treatment in vivo. Oral administration of quercetin was shown to increase exercise tolerance261–263, 
voluntary activity263, markers of mitochondrial biogenesis262,263, and prevention of cardiac muscle 
damage261.  Furthermore, quercetin reduced risk of upper respiratory airway infection in mice after 
stressful exercise upon exposure to influenza264. 
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2.6.1 Seminal studies using quercetin supplementation in athletes 
 Several in vivo studies have been performed in order to clarify the role of quercetin in 
humans under conditions of exercise induced physiological stress.  In a randomized double-blind 
placebo-controlled clinical trial of 26 male untrained badminton players, time to exhaustion was 
significantly decreased in athletes supplemented with 1000mg per day of quercetin for eight weeks265.  
In another cohort of untrained males, supplementation of quercetin for two weeks (1000mg) 
significantly improved treadmill time trial performance266.  However, two independent studies failed 
to measure any benefit of quercetin supplementation (1000mg) on the performance in trained 
cyclists267,268. The disparities observed between these studies could be due to quercetin having greater 
influence on mitochondrial biogenesis in untrained compared to trained athletes. 
 In a randomized placebo controlled study of exhaustive exercise, athletes cycled at 57% 
WattsMAX for 3hrs daily on three consecutive days.  Cyclists supplemented with 1000mg of quercetin 
for five weeks had significantly increased plasma quercetin levels compared to the placebo8,12,269.  
Despite increased plasma quercetin levels, supplementation failed to attenuate increases in plasma 
cytokines post exercise.  Furthermore, muscle NF-kb did not increase post exercise and no difference 
was observed between the quercetin supplemented and placebo groups8,269.  Despite no observable 
difference in immune response following exercise, quercetin supplementation did markedly reduce 
upper respiratory tract infections in the two week period following the three day exhaustive exercise 
program (placebo 45% Vs. quercetin 5%)12.  Similar results were obtained by the same research 
group, in an additional study investigating quercetin supplementation in endurance runners. Runners 
in the western states endurance run were randomized with either placebo or quercetin (1000mg) for 
three weeks prior to the 160km event and for the two weeks following the race. There was no 
significant difference in inflammatory cytokines, performance or immune response in athletes 
supplemented with quercetin compared to the placebo control group270–272.  While a trend in the 
reduction URTI’s was observed in the quercetin supplemented group, this reduction failed to reach 
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significance273.  The authors attribute the lack of significance to the relatively small study size and an 
overall reduced incidence of UTRI as a result of season variation. 
2.6.2 Modulation of quercetin supplement formulation 
Data from those founding studies conducted on quercetin supplementation in vivo failed to 
live up to the standards set by both the flavonoid’s potent anti-inflammatory action in vitro and 
optimistic findings in animal studies.  Of chief concern was the poor bioavailability of quercetin 
aglycone in humans, with levels of plasma quercetin obtained from study participants often falling 
below the 5µM minimal concentration that has been shown to significantly reduce TNF-a levels in 
PMA stimulated human PBMC culture8,250,254,266,269,273–275.  To combat this issue, quercetin 
supplementation was reformulated with other flavonoids and food components that could potentially 
improve quercetin’s bioavailability and bioactive function225,226,276–281.  Additions to the supplement 
included another flavonoid epigallocatechin 3-gallate (EGCG)280,282,283 from tea, a glycosylated form 
of quercetin called isoquercetin (quercetin-3-glucose or hirsutrin)195,276,284, N3polyunsaturated fatty 
acids (N3-PUFA) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)276, and the 
nutrients vitamin C, vitamin B3, and folate279,281. 
To test this newly formulated supplement, a total of 39 trained cyclists were recruited and 
asked to take Q-EGCG, Q-chew (Q-EGCG minus EGCG, isoquercetin, and N3PUFA), or placebo soft 
chew supplements twice a day for a total of 14 days. Following supplementation, participants cycled 
for 3 consecutive days (3 hours per day) at ~57% Wmax.  Cyclists on both Q-EGCG and Q-chew had 
significantly higher levels of plasma quercetin pre-, post-, and 14 hours after exercise compared to 
placebo, with Q-EGCG trending at higher levels then Q-chew285.  Heightened plasma quercetin levels 
in Q-EGCG users correlated with changes in peripheral immune status during recovery, as evidenced 
by reduced total blood leukocyte counts, a 50% reduction in serum CRP, and a decrease in plasma IL-
6 levels that were 39% less then placebo.  In addition, both Q-chew and Q-EGCG groups had a 
significant decrease in plasma levels of IL-10 and G-CSF, post- and 14 hours post-exercise, 
respectively.  Importantly, the observed changes in immune status observed in quercetin 
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supplemented athletes coincided with reduced delayed onset muscle soreness (DOMS) scores at day 2 
and 3 of recovery.  Despite these encouraging findings, it should be noted that not all immune 
perturbations measured in this study were countered by quercetin intervention, since expected rises in 
plasma IL-1ra and MCP levels failed to differ between treatment groups268,286.  Due to the 
experimental design employed in the Q-EGCG study it was not possible to delineate which ingredient 
or combination was responsible for the observed changes in immune status between treatment 
groups285. 
2.6.3 Controversy over nutraceutical anti-inflammatory use in athletes 
Even if direct evidence substantiating the “open window theory” were discovered there are 
those that criticize the use of nutritional supplements to dampen the degree of physiological stressors, 
such as inflammation and oxidative stress, that are thought to accompany infection risk.  The 
principle argument against such interventions suggest that it would interfere with important signaling 
pathways and gene expression essential to adaptations made during exercise training144,145,287.   This 
concern is understandable since many of the dietary supplements in question have potent antioxidant 
potential and could inhibit redox-sensitive pathways such as MAPK, which is said to regulate growth, 
metabolism, differentiation, and remodeling of skeletal muscle288.  Similarly, inhibition of NF-κB is 
also questioned due to its regulation of gene products involved in inflammation and protein 
turnover289.  Also, as previously mentioned, both of these transcription factors upregulate endogenous 
antioxidant enzymes, such as MnSOD, copper-zinc superoxide dismutase (CuZnSOD), GPX, and 
iNOS110.  
 Another issue is that either one of these pathways may regulate expression of the so called 
“myokine” IL-6290.  De novo synthesis of IL-6 in skeletal muscle has been reported in variety of 
conditions, including exercise291,292, muscle inflammation293 and microtrauma294, hypoperfusion295, 
and following denervation296.  Its status as a myokine prototype is said to be especially notable during 
exercise since it precludes other circulating cytokines in both onset and relative abundance290.  
Pedersen et al. 290 has theorized that regulation of IL-6 expression in myocytes is unlike that in 
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macrophages, which is predominately regulated by NF-κB.  Instead it was suggested that IL-6 
signaling in muscle was seemingly more complex implicating both Ca2+/nuclear factor of activated T-
cells (NFAT) and glycogen/p38 mitogen-activated protein kinase (MAPK) pathways in its regulation.  
However, a more recent study has more definitively shown that electric-pulse-stimulation (EPS) of 
C2C12 myotubes specifically activates c-jun terminal kinase (JNK) and activator protein 1 (AP-1), 
with inhibition of JNK completely abolishing all EPS-induced increases in IL-6 gene and protein 
expression.  Therefore, inhibition of classical inflammatory pathways in leukocytes or myocytes alike 
during exercise may have no effect on the regulation of IL-6.  This is an important point to make 
since IL-6 is thought by many to play a beneficial role during exercise by increasing glucose 
production in the liver and lipolysis in fat tissue297.  In addition, IL-6 present in circulation during 
exercise has been identified as the trigger for IL-10 and IL-1ra in blood leukocytes153.  IL-10 inhibits 
production of a multitude of inflammatory cytokines298–300 and IL-1ra functions to inhibit IL-10 
receptor binding301. 
 Interestingly, a recent study by Marklund et al.302, conducted on nine experienced athletes 
participating in a 24-hour ultra-endurance event provided evidence to suggest that intensive exercise 
increases expression of major histocompatibility complex I (MHC I) in both the cytoplasm and 
sarcolemma of skeletal muscle fibers303.  Upregulated MHC class I expression is traditionally a pre-
requisite for antigen-specific CD8 mediated cytotoxicity, and thus is not expressed at detectable 
levels in normal human skeletal muscle303–305.  In addition, they also found a significant inflammatory 
cell infiltration in the skeletal muscle, with a 2-3 fold higher number of CD3+, CD8+, and CD68+ 
cells302.  Prior to this study only three other studies have addressed local skeletal muscle inflammation 
in response to endurance exercise, only two of which reported inflammatory infiltration into skeletal 
muscle following marathon running306–308.  Additionally, increased expression of MHC class-I in the 
sarcolemma of muscle fibers has previously only been shown in autoimmune muscle diseases that 
result in muscle cell damage and myositis305,309–312.  This leads one to speculate as to whether 
increased MHC class-I expression with an accompanied infiltration of inflammatory cells could be 
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responsible for the typical muscle damage procured during sustained, intense exertion of marathon 
and ultramarathon races.  In support of this idea, a study conducted in 2000 found biochemical and 
histological features of myositis after over-expression of a mouse MHC I gene, H-2Kb, by linking it 
to a constitutively active creatine kinase promoter313.  If substantial leukocyte infiltration obtained 
during sustained, endurance exercise is the causative agent of increased infection risk in these elite 
athletes, then it would seem appropriate to target traditional inflammatory pathways, such as NF-κB, 
in an attempt to blunt the detrimental effects of this superfluous inflammation on an athlete’s health 
and performance. 
2.7 Purpose 
 As previously discussed, there are a number of in vitro studies that have linked quercetin’s 
anti-inflammatory capabilities to the modulation of signaling pathways vital to cell function.  These 
actions include a diminished release of pro-inflammatory cytokines by inhibiting cell signaling that 
would otherwise lead to the activation of the transcription factor NF-κB.  However, no study has 
analyzed the anti-inflammatory activity of the in vivo metabolites of quercetin in vitro using human 
peripheral blood mononuclear cells (PBMCs).  The in vitro study utilizing human PBMCs detailed in 
this thesis will be the first to characterize the anti-inflammatory properties of two quercetin 
metabolites, quercetin-3’-sulfate and quercetin-3-glucuronide, incorporating levels mimicking those 
found in human blood plasma after digestion of quercetin.  Findings from this in vitro study may help 
explain why quercetin failed to counter exercise-induced inflammation in preliminary human studies. 
 Using the same in vitro model, quercetin and 45% EGCG enriched green tea extract will be 
tested both alone and in various combinations to determine the optimal amounts and proportions.  The 
goal will be to develop a quercetin-green tea extract supplement that exerted a strong in vitro anti-
inflammatory effect, which could then be tested in vivo. 
 Building on results found in the in vitro study, an additional animal study will be conducted 
to determine the optimal dosing regimen with a quercetin-green tea extract supplement to counter 
exercise-induced inflammation.  Experiments with mice will be designed to test the amount and 
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duration of quercetin-green tea extract supplementation that exerts the best anti-inflammatory 
influences post-exercise.  
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Chapter 3: Materials and methods 
3.1 In Vitro Study 
3.1.1 Peripheral Blood Mononuclear Cell (PBMC) isolation 
Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA-treated venous 
peripheral blood harvested from healthy, male and female human volunteers (age 18-30) by a low-
density iodixanol density barrier method.  The institutional review board (IRB) of Appalachian State 
University approved the protocol for the collection of human blood in this study (#10-0185).  All 
participants were fully cognizant of the aim and details of the study and gave their written informed 
consent. 
PBMC isolation was performed using a low-density iodixanol density barrier method.  This 
was accomplished by first adjusting the density of plasma in whole blood to r = 1.095 g/ml with a 
working solution (WS) of 40% (w/v) iodixanol, a 1:3 dilution of Optiprep® Density Gradient Medium 
(Sigma Aldrich, St. Louis, MO, USA) in 0.85% (w/v) NaCl and 30 mM Tricine-NaOH, pH 7.4.  
Aliquots (5 ml) of this suspension were layered underneath equivalent volumes of r = 1.078 g/ml 
density barrier solution, a 1:2.92 dilution of WS in tricine buffered saline (0.85% NaCL, 10 mM 
Tricine-NaOH, pH 7.4).  Density separation was achieved by centrifugation at 700xg and 20°C for 30 
minutes with slow acceleration and no brake.  Resolved, mononuclear cell fractions (1.068 g/ml 
layer) were collected and washed twice at 400xg and 20°C for 10 minutes, with normal acceleration 
and deceleration, in RPMI-1640 medium (Sigma-Aldrich, Saint Louis, MO, USA) containing 10% 
fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA) supplemented with 200 mM 
GlutaMAX (Life Technologies, Grand Island, NY, USA); 10,000 U/ml & 10 mg/ml penicillin 
streptomycin, respectively (Sigma Aldrich, Saint Louis, MO, USA); and 100mM sodium pyruvate 
(Sigma-Aldrich, Saint Louis, MO, USA) (C-RPMI). 
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3.1.2 Flavonoid preparation 
 Quercetin, purchased from Sigma-Aldrich (Saint Louis, MO, USA), was dissolved in 
dimethyl sulfoxide (DMSO) before being diluted in C-RMPI.  DMSO is a known antioxidant capable 
of scavenging hydroxyl radicals314.  Therefore, to eliminate any confounding effects DMSO may have 
on PBMC inflammatory status, quercetin stocks were prepared at 1324-fold of each respective 
concentration used in culture, such that DMSO was <0.01% and consistent across treatments.  An 
equivalent concentration of DMSO was also included in all controls and treatment groups lacking 
quercetin. Dulbecco’s phosphate buffered saline (PBS) (Sigma-Aldrich, Saint Louis, MO, USA) was 
used as vehicle for both green tea extract containing 45% EGCG was purchased from NutriScience 
Innovations LLC (Trumbull, CT), and the hydrophilic quercetin conjugates quercetin-3-glucuronide 
(Q3GlcA) and quercetin-3’-sulphate (Q3’S), were provided by Professor P. W. Needs from the 
Institute of Food Research (Norfolk, UK). 
3.1.3 Flavonoid treatment of LPS stimulated PBMC cultures 
Isolated PBMCs were adjusted to a concentration of 1x106 cell/ml with C-RPMI.  Cell counts 
were performed using either a CountessTM automated cell counter (Life Technologies, Grand Island, 
NY, USA) or by flow cytometry using uniform sized flow-count fluorospheres (Beckman Coulter, 
Fullerton, CA, USA).  Prior to using the automated cell counter 200 µl of a 1:10 dilution of each 5ml 
cell suspension was prepared in PBS, 10 µl of which was further diluted in an equal volume of 
supplied trypan blue stain before loading into a disposable chamber slide and read by the cell counter.  
For absolute count by flow cytometric analysis, 100 µl of each 5 ml cell suspension was combined 
with 100 µl of flow-count fluorospheres in 1 ml of PBS. Fluorospheres were detected on florescence 
channel 3 (FL3) of a Beckman Coulter FC-500 flow cytometer with lymphocyte subsets gated using 
linear forward scatter and side scatter intensity using CXP software (Beckman Coulter, Fullerton, CA, 
USA).  Absolute counts were calculated using the following formula: cells/µl = [(cells 
counted)/(fluorospheres counted)] x (fluorosphere assayed concentration of 1025). 
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 PBMCs were seeded into flat bottom 24-well culture plates (1x106 cells/well), flat bottom 96-
well culture plates (1x105cells/well), and 75 cm2 culture flasks (1x107 cells/flask) for cytokine, 
metabolic activity, and western blot analyses, respectively.  Quercetin, 45% EGCG enriched green tea 
extract, quercetin-3-glucuronide (Q3GlcA), and quercetin-3’-sulphate (Q3’S) were diluted 1:6 for 
each replicate to achieve final concentrations of 1, 2, 10, 25, 40, and 50 µM.  PBMCs were incubated 
at 37°C and 5% CO2 with 1 hour pretreatment with flavonoids followed by 23 hours of stimulation 
with 0.1 µg/ml of lipopolysaccharides (LPS) from Escherichia coli 055:B5 (Sigma-Aldrich, Saint 
Louis, MO, USA). 
3.1.4 Metabolic activity 
 Tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)2H-5-tetrazolio]-1,3-benzene 
disulfonate) (Roche Diagnostics, Indianapolis, IN, USA) is cleaved to formazan by succinate 
dehydrogenases in metabolically active cells and therefore indicative of cell viability.  PBMCs (100 
µl, 1x106 cells/ml) used in this assay were cultured in parallel with those used for cytokine analyses, 
supplementing with the same concentration ranges and combinations of flavonoids (12.5 µl) in a total 
volume of 125 µl.  LPS stimulation (25 µl, 0.1 µg/ml) was performed after 1 hour of the 24 hour 
incubation period at 37°C, 5% CO2.  WST-1 reagent was added (15 µl/well) 4 hours prior to the end 
of the incubation period at which point the plate was allowed to incubate at room temperature for 5 
minutes before measuring the absorbance of each sample by a microplate (ELISA) reader at 450 nm. 
3.1.5 Cytokine quantification by ELISA 
 The concentration of tumor necrosis factor alpha (TNF-a) in culture medium was determined 
using an enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer’s 
instructions (R&D Systems, Minneapolis, MN).  Standards were prepared by making a 100-fold 
dilution of the provided recombinant human TNF-a (10,000 pg/ml) in animal serum (diluted stock 
calibrator) followed by a 4-fold serial dilution for standards ranging from 2500 pg/ml to 0.61 pg/ml.  
96-well polystyrene plate pre-coated with monoclonal mouse anti-human TNF-α was equilibrated 
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with a buffered protein base (assay diluent RD1F) (50 µl/well) before addition of standard, sample, or 
control (200 µl/well) in duplicate.  Following a two-hour room temperature incubation, wells were 
aspirated and washed by automated cell washer with provided wash solution consisting of buffered 
surfactant (400 µl/well) 4 times, inverting plates and blotting against paper towels after each wash to 
ensure complete removal of liquid.  A polyclonal antibody against human TNF-a conjugated to 
horseradish peroxidase was then added (200 µl/well) and plates incubated at room temperature for 1 
hour.  Previous aspiration/wash steps were repeated before adding substrate solution (200 µl/well), a 
1:1 combination of hydrogen peroxide and chromogen, and incubating for an additional 20 minutes in 
the dark at room temperature.  2 N sulfuric acid (50 µl/well) was added to terminate the reaction and 
optical density was measured at 450 nm using a microplate (ELISA) reader. 
3.1.6 Supernatant cytokine quantification by multi-spot electrochemiluminescence detection 
 Concentrations of TNF-a, interleukin 6 (IL-6), IL-8, and IL-1b in culture medium were 
determined using a multi-spot electrochemiluminescence detection assay developed by Meso Scale 
Discovery (MSD) (Rockville, MD, USA).  All reagents, equipment, and consumables were supplied 
in MSD’s human proinflammatory-4 II tissue culture kit and the assay was performed according to 
the manufacturer’s instructions.  Standards were prepared by performing a 1:10 dilution of the 
supplied 1µg/ml stock solution in diluent 2, followed by a 1:4 dilution series from 10000 pg/ml to 2.4 
pg/ml.  MSD plates pre-coated with capture antibodies for the specific cytokines listed were initially 
incubated for 30 minutes with diluent 2 (25 µl/well) with vigorous shaking (850 rpm) at room 
temperature.  Standards, samples, and blanks were then added in duplicate (25 µl/well) and incubated 
at room temperature for 2 hours with vigorous shaking (850 rpm).  To remove any unbound antibody 
plates were washed with PBS containing 0.05% Tween-20 (PBS-T) using an automated plate washer.  
Detection antibody mix containing antibodies against TNF-a, IL-6, IL-8, and IL-1b, and conjugated 
with MSD SULFO-TAG was added (25 µl/well) and plates incubated for 2 hours as before.  Finally, 
after an additional three washes in PBS-T, 2X read buffer T was added (150 µl/well) and the plates 
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analyzed using discovery workbench 3.0 software on a SECTOR Imager 6000 (MSD, Rockville, MD, 
USA).  The minimum detectable concentration of TNF-a was 1.0 pg/mL, IL-6 0.7 pg/mL, IL-8 0.7 
pg/mL, and IL-1b 0.4 pg/mL. 
3.1.7 Western blot analysis 
3.1.7.1 Protein extraction from PBMCs 
 1x107 PBMCs were cultured in 75cm2 culture flasks, pretreating with a 1:6 dilution of 25 µM 
Quercetin and 5 µM EGCG alone or in combination in a total of 12.5 ml of C-RPMI for one hour 
followed by stimulation with LPS (0.1 µg/ml) for 30 minutes.  To collect non-adherent lymphocytes, 
supernatant was centrifuged (400xg, 4°C) for 5 minutes.   Lymphocytes and remaining adherent 
monocytes were each washed in ice cold PBS.  Lymphocytes were then pelleted (400xg, 5 minutes, 
4°C) before resuspension in 400 uL 1X RIPA buffer (0.15M NaCL; 0.5% sodium deoxycholate; 1% 
Triton X-100; 0.1% sodium dodecyl sulfate; 50mM Tris-HCl, pH 7.4), containing a broad spectrum 
halt protease and phosphatase inhibitor cocktail (Pierce, Rockland, IL, USA).  RIPA suspensions of 
lysed lymphocytes were to their respective culture flasks to lyse remaining monocytes, and incubated 
on ice for 5 minutes.  To ensure complete lysis and reduce viscosity, flasks were scrapped, lysate 
transferred to microcentrifuge tubes, and sonicated for 12 seconds. 
3.1.7.2 Protein quantification and preparation 
 Protein concentration was determined using a BCA protein assay kit according to the 
manufacturer’s instructions (Pierce, Rockland, IL, USA).  Concentration of samples was measured 
relative to an albumin standard at a working range of 20-2,000 µg/ml.  Samples, standards, and blanks 
(25 µl/well) were added in duplicate to a 96-well plate (200 µl/well) in combination with working 
reagent, a 50:1 preparation of reagent A (sodium carbonate, sodium bicarbonate, bicinchoninic acid 
and sodium tartarte in 0.1N sodium hydroxide) and reagent B (4% cupric sulfate).  Plates were 
incubated at 37°C for 30 minutes, then absorbance was measured at 562nm on a microplate (ELISA) 
reader once the plate had reached room temperature. 
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Thirty micrograms of total protein was prepared by first ensuring an equivalent loading 
volume across samples by diluting up to the volume of the most concentrated sample.  Diluted protein 
was then suspended in 3X laemmli buffer consisting of 187.5mM Tris-HCL pH 6.8, 6% w/v SDS, 
30% glycerol, 0.03% bromophenol blue, and 150mM dithiothreitol (DTT).  Prior to separation by 
electrophoresis, protein samples were reduced by heating at 95-100°C for 10 minutes, incubated on 
ice for 5 minutes, and centrifuged at max speed for 5 minutes. 
3.1.7.3 Electrophoresis 
 PBMC protein was separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) at 200 Volts (V) for 45 minutes.  Running buffer used was 25 mM Tris base (EMD 
Chemicals, Gibbstown, NJ, USA), 192 mM glycine (Sigma-Aldrich, Saint Louis, MO, USA), and 
0.1% w/v SDS. Resolving gels consisted of 10% w/v acrylamide:bis 29:1 (EMD Millipore, Billerica, 
MA, USA), 391 mM Tris-HCl pH 8.8, 3.468mM SDS (Sigma-Aldrich, Saint Louis, MO, USA), and 
4.383 mM ammonium persulphate (AMRESCO, Solon, OH, USA). Stacking gels consisted of 6.6% 
w/v acrylamide:bis 29:1, 0.992M Tris-HCL pH 6.8, 0.1% w/v SDS, 0.1% w/v ammonium 
persulphate.  Both resolving and stacking gels were polymerized with 4 µl TEMED (Fisher Scientific, 
Fair Lawn, NJ, USA). 
3.1.7.4 Protein transfer 
 Protein was transferred from resolving polyacrylamide gel to a nitrocellulose membrane 
(BioRad, Hercules, CA, USA) at 100 V for 1 hour at 4°C.  Transfer buffer used was 25 mM Tris 
Base, 192 mM glycine, 0.1% SDS, and 20% v/v methanol (Fisher Scientific, Fair Lawn, NJ, USA).  
To ensure transfer was complete, the gel was rinsed with deionized water and then incubated in 
comassie stain for 1 hour at room temperature.  To visualize protein on the nitrocellulose membrane, 
it was immersed in a sufficient amount of Ponceau S stain for 5 minutes with gentle shaking and then 
rinsed with deionized water until membrane background was white.  Following confirmation of 
protein transfer, the membrane was washed for 5 minutes in 50 ml tricine buffered saline (TBS) and 
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0.1% Tween 20 (TBS/T).  TBS used was diluted from a 10X stock consisting of 200 mM Tris base, 
1.369 M sodium chloride (NaCl), with pH adjusted to 7.6 using HCl. 
3.1.7.5 Blocking and antibody incubations 
 For specific detection of phosphorylated proteins, the membrane was blocked for 1 hour at 
room temperature in TBS/T containing 5% Blotto (nonfat dry milk) (Santa Cruz Biotechnology, 
Dallas, TX, USA).  Then after three 10 minute washes with 50 ml TBS/T, it was probed overnight at 
4°C with 1:2000 dilutions of monoclonal rabbit anti-human antibodies directed against phospho-NF-
kB p65 (Ser536) and b-actin (13E5) (Cell Signaling Technology, Danvers, MA, USA) in TBS/T 
containing 5% bovine serum albumin (BSA) (Sigma-Aldrich, Saint Louis, MO, USA). Following the 
overnight incubation, the membrane was washed again (three 10 minute washes 3 in 50 ml TBS/T) 
prior to a 1 hour, room temperature incubation with secondary, a 1:6000 dilution of goat anti-rabbit 
IgG (H+L) conjugated to alkaline phosphatase (AP) in TBS/T containing 5% Blotto. 
3.1.7.6 Substrate addition and development 
Following a final wash series (three 10 minute washes with 50 ml TBS/T) chemiluminescent 
detection was achieved using 2 ml Immun-Star chemiluminescent substrate containing 100 µl of 
enhancer reagent (BioRad, Hercules, CA, USA).  This signal was developed using an automated x-
ray film developer on Amersham hyperfilm ECL (GE Healthcare Biosciences, Pittsburgh, PA, USA).  
Film was scanned and intensities of bands measured using ImageJ (National Institutes of Health), 
normalizing to the b-actin signal. 
3.2 In Vivo Study 
3.2.1 In vivo experimental design 
 Adult, male C57BL/6J mice (n=116) were purchased from Jackson Laboratory.  Protocols 
were approved by the North Carolina Research Campus Institutional Animal Care and Use 
Committee (IACUC No 11-007). 
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Mice were randomly assigned to one of five groups: control, 6.25 mg Quercetin/kg and 1.25 
mg EGCG/kg (Q/EGCG low), 12.5 mg Quercetin/kg and 2.5 mg EGCG/kg (Q/EGCG mid), and 25 
mg Quercetin/kg and 5 mg EGCG/kg (Q/EGCG high), and 25 mg Quercetin/kg only (Q).  Animals 
were given quercetin/EGCG extract through their food (Bio-Serve Inc.) ad libitum.  Within each 
group, animals were randomly assigned to 3 or 14 days of supplementation, resulting in 10 groups 
(n=11-12 animals per group).  For the last three days of the dosing cycle, mice were run on a 
treadmill at 14 meters/minute (0% grade) for up to 2.5 hours to induce exercise induced inflammation 
and oxidative stress.  Immediately following exercise on the third day, mice were put under isoflurane 
anesthesia and euthanized by exsanguination via a needle puncture to the abdominal aorta.  Blood 
was immediately injected into EDTA-coated 1-ml microtainer tubes, and resultant plasma snap frozen 
in liquid nitrogen and stored at -80°C until analysis. 
3.2.2 Plasma quercetin 
 Total plasma quercetin (quercetin and its primary conjugates) was measured following solid-
phase extraction via reverse-phase HPLC with UV detection as previously described315.  Quercetin 
conjugates were hydrolyzed by incubating 500 µL plasma aliquots with 10 µL 10% DL-dithiothreitol 
(DTT) solution.  50 µL 0.58 M acetic acid, 50 µL of a mixture of b-glucuronidase and arylsulfatase, 
and crude extract from Helix pomatia (Roche Diagnostics, Mannheim, Germany) for 2 hours at 37°C.  
Chromatographic analysis was performed using the Ultimate 3000 HPCL-PDA system (Dionex 
Corporation, Sunnyvale, CA) with a Gemini C18 column (Phenomenex, Torrance, CA). 
3.2.3 Plasma cytokine detection by multi-spot electrochemiluminescence 
 Concentrations of interferon-g (INF-g), IL-1b, IL-10, IL-12p70, IL-6, KC/GRO/CINC 
(CXCL1), TNF-a in EDTA-treated plasma were determined by an electrochemiluminescence 
detection assay (MSD, Rockville, MD, USA).  All reagents, consumables, and equipment were 
supplied in MSD’s mouse pro-inflammatory 7-plex ultra-sensitive kit and the assay performed 
according to the manufacturer’s instructions.  The same procedure was followed as that used for 
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human tissue culture samples, except that diluent 4 was used in place of diluent 2 and the 7 standards 
ranged from 10,000 pg/ml to 2.4 pg/ml.  The minimum detectable concentration of INF-g was 0.38 
pg/mL, IL-1b 0.75 pg/mL, IL-10 11 pg/mL, IL-12p70 35 pg/mL, IL-6 4.5 pg/mL, CXCL1 3.3 pg/mL, 
and TNF-a 0.85 pg/mL.  
3.3 Statistical Analysis 
Cytokine data are expressed as mean ± standard error (SE).  Standards generated within MSD 
assays were screened for a % bias between 80 and 120% before calculating sample concentration 
using a four-parameter logistic model within discovery benchtop 3.0 (MSD, Rockville, MD, USA).  
Outliers, defined as observations that were greater or less than 2.5 standard deviations from the 
respective treatment mean, were eliminated from further statistical analysis.  Data were then 
compared between treatment groups of each study design by using an analysis of covariance 
(ANCOVA) run in SPSS version 20 (IBM, Armonk, NY, USA), controlling for PBMC metabolic 
activity and mouse weight loss during run within in vitro (EGCG and quercetin, including aglycone 
and conjugates) and in vivo (plasma cytokine and run time) data sets, respectively.  In vitro metabolic 
activity data was analyzed using a one-way ANOVA with a post-hoc Bonferroni test conducted 
relative to baseline stimulated control. 
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CHAPTER 4: Results 
4.1 In Vitro Anti-Inflammatory Potential of Quercetin 
4.1.1 Effect of quercetin on LPS-stimulated PBMC response 
 To initially test quercetin’s anti-inflammatory potential, an in vitro inflammatory response 
was evoked in human peripheral mononuclear cells (PBMCs) isolated from healthy donors using 
lipopolysaccharide (LPS), a glycolipid component of the cell wall in gram-negative bacteria.  Data 
from preliminary experiments showed that exposure to 0.1 µg/ml of LPS for 23 hours was sufficient 
to significantly increase levels of the pro-inflammatory cytokine TNF-α in PBMC supernatants 
relative to non-stimulated controls (data not shown).  When pretreated with quercetin aglycone for 1 
hour, PBMCs displayed a dose-dependent reduction in TNF-α release, reaching significance at or 
above 25 µM (F=10.700; p<0.0001) (Fig. 1A).  Additionally, these doses of quercetin were able to 
significantly decrease levels of other cytokines indicative of an incurring inflammatory event, such as 
IL-1β and IL-6, when measured in a multiplex electrochemiluminescent array (F=11.488 and 13.675, 
respectively; p<0.0001) (Fig. 1B-C).  Levels of IL-8, a major mediator of the inflammatory response 
that functions as a chemoattractant, were also significantly lower in quercetin treated cells relative to 
stimulated controls, but only at the highest concentration tested (50µM) (Fig. 1D). 
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4.1.2 Metabolic activity 
 Metabolic activity was measured in parallel to inflammatory cytokine secretion to determine 
the effects of QUE treatment on cell viability.  Approximately 26.3% (partial eta squared value) of 
the variability in PBMC metabolic activity could be accounted for by dosage of quercetin 
supplemented.  As shown in Fig. 2, metabolic activity was significantly decreased at 40 and 50 µM 
QUE when compared to stimulated controls (F=5.302; p<0.0001).  To control for these effects, 
subsequent inflammatory cytokine secretion data was analyzed by first adjusting for differences in 
PBMC metabolic activity relative to stimulated, positive controls.  Notably, cells treated with 25 µM 
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QUE maintained a mean relative metabolic activity of 92.58% and after correcting for bias by this 
covariate, continued to significantly inhibit TNF-α, IL-1β, and IL-6 secretion (Fig. 1,2). 
 
4.1.3 Effect of quercetin conjugates on LPS-stimulated PBMC response 
 It is generally accepted that ingestion of quercetin in either its glycoside or aglycone form 
must undergo significant modification prior to its bioavailability in the systemic circulation.  Upon 
absorption in the small intestine and subsequent processing by the liver, the aglycone can be modified 
by conjugation reactions, such as sulfation and/or glucuronidation, and by methylation of hydroxyl 
groups present on its catechol-ring by the enzyme catechol-O-methyltransferase.  Therefore, this 
study tested, two of the three most abundant human plasma quercetin conjugates, quercetin-3-
glucuronide (Q3GlcA) and quercetin-3'sulfate (Q3'S), in the in vitro LPS-stimulated PBMC model 
previously established.  Neither Q3GlcA nor Q3'S at concentrations ranging from 1-40 µM 
significantly inhibited LPS-induced inflammatory cytokine secretion when compared to untreated 
controls (Fig. 3-4).  Parallel measurements of metabolic activity indicated that greater than 95% of the 
cells remained viable at the highest concentration of either conjugate compared to baseline, 
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stimulated controls (Fig. 5).  These data were anticipated since conjugation decreases a flavonoid's 
lipophilicity and would not favor their passive diffusion through PBMC cellular membranes.  In the 
absence of some unknown, specific transport system or interaction with a yet unidentified surface 
receptor, the hydrophilic nature of Q3GlcA and Q3'S would likely prevent any effects these 
metabolites may have on PBMC homeostasis.  Supplies of Q3GLcA and Q3'S were limited thus 
concentrations as high as 50µM could not be tested. 
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4.1.4 Quercetin & EGCG in combination: Assessing putative synergistic effects 
 Previously it has been shown that endurance athletes receiving 1000-mg quercetin per day for 
up to 3 weeks failed to counter exercise-induced inflammation incurred during the heavy exertion of 
competition8.  However, only two weeks of quercetin supplementation was sufficient to significantly 
decrease C-reactive protein (CRP) and plasma levels of IL-6 and the anti-inflammatory mediator IL-
10 following a three-day period of intense exercise when combined with EGCG, isoquercetin, 
eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)268.  To further explore how the 
addition of these compounds might improve quercetin's bioactive effects, EGCG was combined with 
quercetin at different ratios to supplement ex vivo human PBMCs.  Ratios tested included QUE (µM): 
EGCG (µM) at 5:5, 10:5, 10:10, 25:10, and 25:25.  As shown in Fig. 6, none of the quercetin to 
EGCG ratios tested significantly inhibited TNF-α secretion from LPS-stimulated PBMCs.  On 
average 25 µM of quercetin combined with 10 µM of EGCG was sufficient to cause a 3.89 fold 
decrease in TNF-α, yet this failed to be significant after adjusting for metabolic activity.   
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 To assess the effects of EGCG alone on PBMC inflammatory response or viability, EGCG 
was added without quercetin at different concentrations.  EGCG dose dependently increased TNF-α 
levels in PBMC supernatant after 23 hours of incubation with LPS, which reached significance 
(p<0.001) at the highest concentration tested (50 µM) (Fig. 7A).  Accordingly, metabolic activity 
relative to stimulated controls was significantly reduced when cells were pretreated with either 25 or 
50 µM EGCG (Fig. 7B).  These data suggest that EGCG supplemented in this culture system has a 
negative impact on cell viability and can potentially amplify an inflammatory response at doses at or 
greater than 50 µM. 
  
4.2 In Vivo Anti-Inflammatory Potential of Quercetin 
4.2.1 Selection of a quercetin to EGCG ratio based on in vitro findings 
 Despite the fact that in vitro results for this study provided no direct evidence to substantiate 
claims that EGCG was necessary to improve quercetin's effectiveness as an anti-inflammatory agent 
in humans, this did not rule out a role for EGCG in quercetin bioavailability.  Herein, quercetin has 
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been shown to decrease expression of inflammatory markers at the high concentration of 25 µM, 
without significantly affecting cell viability.  Observations of similar anti-inflammatory action in vivo 
may only require improvements on its dietary absorption and accumulation in tissue rather than 
synergistically amplifying its bioactive effects within cells.   
To determine if coingestion of EGCG was required to obtain anti-inflammatory effects from 
quercetin supplementation, its impact would need to be measured using an in vivo experimental 
design.  Due to EGCG's detrimental effect on cell viability with increasing concentration in culture, 
its dose relative to quercetin was kept minimal.  With that in mind, a 5:1 ratio of quercetin to EGCG 
was selected to formulate diets to dose C57BL/6J mice.  In vitro testing of this ratio was performed 
prior to the animal study to ensure that EGCG did not affect quercetin’s bioactive effects on LPS-
stimulated PBMC response.  Additionally, 25 µM of quercetin was used in this final cell culture 
experiment since this concentration had previously caused a significant decrease in TNF-α secretion 
when correcting for metabolic activity.  As seen in Fig. 8A-C, QUE and EGCG at a ratio of 5:1 
significantly decreased secretion of both IL-1β and IL-6 from PBMCs after adjusting for metabolic 
activity.  In this experiment QUE failed to significantly decrease TNF-α secretion, which was likely 
due to the sample size being limited to 5 donors compared to prior experiments, which were 
representative of 14 donors.   On average TNF-α secretion from PBMCs supplemented with QUE and 
EGCG combined approximated that of QUE alone.  Taken together, these results indicated that 
additional supplementation of EGCG when concentration was kept five times lower then that of QUE, 
had no adverse effect QUE’s bioactive effects in vitro. 
LPS is known to stimulate the canonical activation of transcription factor NF-kB via toll-like 
receptor 4 (TLR-4) to cause upregulated expression of TNF-α, IL-6, and IL-1β in macrophages.  
Furthermore, it has been demonstrated that LPS stimulation can induce phosphorylation of serine 536 
on the trans-activation domain of NF-κB subunit p65 in an IKK-dependent manner to increase 
transcriptional activity.  To determine if QUE supplementation affected NF-κB transcriptional 
activity in this manner, PBMC protein lysates were probed with a monoclonal antibody specific to 
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p65 only when phosphorylated at serine 536.  As seen in Fig. 8D, QUE alone or combined with 
EGCG was able to decrease p65 phosphorylation in LPS-stimulated PBMCs to baseline levels 
observed in un-stimulated controls.  
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4.2.2 QUE and EGCG supplementation in mice  
 Diets were formulated for C57BL/6J mice with quercetin concentrations at 25, 12.5, and 6.25 
mg/kg combined with 5, 2.5, and 1.25 kg/mg EGCG at a 5:1 ratio, with an additional treatment group 
receiving only quercetin at the high 25 mg/kg concentration.  Plasma quercetin levels were similar 
even at the highest 25 mg/kg concentration regardless of supplementation length in the absence of 
EGCG at 155.71 and 151.00 ug/L for 3 and 14-day dosing, respectively.  However, when plasma 
quercetin levels for treatment groups receiving EGCG were compared, 14-day supplementation 
tended to have higher plasma quercetin levels then 3-day (Fig. 9). 
4.2.3 Post-exercise inflammatory response following QUE and EGCG supplementation 
 Intense and prolonged exercise has been shown to increase levels of both pro- and anti-
inflammatory cytokines in the plasma of both animals and humans alike.  To determine if QUE alone 
or combined with EGCG at a ratio of 5:1 had any effect on this post-exercise cytokine response, male 
C57BL/6J completing either 3- or 14-day dosing cycles participated in treadmill running for 2.5 hours 
or until exhaustion for 3 consecutive days.  Fig. 10 shows plasma cytokine levels immediately 
following the final exercise bout after adjusting for weight loss during the run.  Of all the cytokines 
measured, only IL-10 was significantly decreased after exhaustive exercise in mice supplemented for 
14 days.  However, these results remain inconclusive since IL-10 measured in the 14-day flavonoid 
supplementation group failed to significantly differ from either 3-day control or supplemented mice.  
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4.4.4 QUE’s effect on exercise performance when combined with EGCG 
 The extent to which mice were allowed to run on a given day in this study was capped at 2.5 
hours.  However, since mice were naïve to this level of exercise, many fatigued before completing the 
maximal running time, which occurred more often on day 1 compared to day 3 of exercise.  For 
example, 14-day supplemented mice along with control ran on average for 135.2, 143, and 149.5 
minutes for exercise day 1, 2, and 3, respectively.  To see if diet had any effect on running 
performance over the course of the three exercise days, the difference in average run time of 
supplement groups was measured relative to control (Fig. 11).  After adjusting for weight loss, neither 
3-day (F=1.312, p=0.2779) nor 14-day (F=2.331, p=0.0677) supplemented groups showed 
significantly improved run time.  
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CHAPTER 5: Discussion 
 Prolonged and intensive exercise, such as marathon and ultramarathon race events, intensify 
the inflammatory response within working muscle, resulting in tissue damage, systemic 
inflammation, and marked increases in oxidative stress4,316,317.  To this effect, responding de novo 
translation of pro-inflammatory cytokine genes, such as IL-6, IL-8, IL-1β, and TNF-α, and a key 
enzyme in prostaglandin production cyclooxygenase-2 (COX-2) have been measured in abundance in 
post-exercise muscle biopsies in humans, with 20 to 30-fold increases reported in IL-6 and IL-8 
mRNA4,7,8.  Furthermore, it is speculated that IL-1β can induce NF-κB regulated expression of IL-6 in 
an autocrine or paracrine fashion within muscle that is distinct from its expression in response to 
contraction via JNK318.  This degree of cytokine expression and secretion, along with profound 
increases in hormones, such as cortisol, and local and systemic oxidative stress, is said to be 
indicative of the degree of physiological stress that could predispose an athlete to increased infection 
risk.  Athletes have in the past been known to take medication for this very reason.  However, over 
the counter nonsteroidal anti-inflammatory medications (NSAIDS), such as ibuprofen, have been 
shown to increase gastrointestinal permeability and endotoxemia following prolonged endurance 
events4,13. 
 Blunting exorbitant inflammation in athletes may be an effective means to counter exercise-
induced alterations in immune status, improving overall recovery and subsequent performance.  
Flavonoids offer an attractive alternative to these medications since they have not been linked to any 
adverse side effects in athletes and are strong antioxidants with putative anti-inflammatory action319.  
Numerous in vitro studies have been conducted on the anti-inflammatory potential of quercetin, a 
flavonoid with metal-chelating ability and high antioxidant capacity.  The present study has 
confirmed previous findings of quercetin’s anti-inflammatory capacity in vitro250,253,254.  
Concentrations of the aglycone supplement tested at or greater than 25 µM significantly decreased 
secretory levels of TNF-α, IL-6, and IL-1β in ex vivo derived human PBMCs following LPS 
stimulation. 
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Despite quercetin’s well-established immune modulating activity in vitro, to date similar 
findings in an in vivo setting have yet to be reported.  In two separate studies, cyclists receiving 1,000 
mg of quercetin per day for three weeks failed to counter inflammatory or oxidative perturbations 
post-exercise compared to placebo8,286.  A plausible explanation for this discrepancy may lie in the 
pharmacokinetics of the compound.  Following intestinal uptake and hepatic processing, circulating 
forms of the polyphenol exist as conjugated derivatives of the ingested aglycone.  Numerous studies 
have reported changes in biological activity upon metabolic transformation of flavonoids188,227,320–322.  
Indeed, the presence of a 3’ hydroxyl group within the B-ring and a 2,3-double bond within the C-
ring of quercetin’s phenylbenzopyrone structure has been reported to have a profound effect on its 
ability to counter leukotriene B4 (LTB4) formation in ex vivo derived human, peripheral monocytes 
and neutrophils 323.  In a similar manner, the present study has established that metabolic derivatives 
of quercetin, quercetin-3’-sulphate and quercetin-3’-O-glucuronide, exhibit a diminished bioactive 
effect on LPS stimulated pro-inflammatory cytokine production in ex vivo derived human PBMCs.  
The precise mechanism by which conjugation in this manner diminishes the anti-inflammatory 
activity of these metabolites cannot be determined based on these experiments.  However, the 
addition of polar moieties such as glucuronide and sulfate has been reported to significantly diminish 
cellular uptake of quercetin in neutrophils323.  Furthermore, it has been recently noted that the 
majority of ingested quercetin and other polyphenolics reach the colon where resident bacteria 
degrade them to smaller phenolics.  A human metabolomics profile on serum collected immediately 
following three days of running 2.5 hours/day, 70% VO2max revealed a significant increase in these 
phenolics compared to 14 hours post-exercise.  It is conceivable that the anti-inflammatory effect 
exhibited by Q-EGCG was elicited by these smaller phenolics and dependent on their accumulation in 
tissue324. 
Another explanation for quercetin’s poor effect in vivo may be linked to the bioavailability of 
the compound.  Intestinal absorption of dietary quercetin aglycone is said to be at most 24%, with 
plasma levels ranging from 0.9 to 7 µM, well below concentrations shown to effectively reduce pro-
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inflammatory cytokine production in vitro8,234,266,268,269,273–275,286.  Consistent with these previous 
findings, plasma levels in the present study reached only as high as 150 mg/L or 0.5 µM in C57BL/6J 
mice supplemented on 25 mg/kg quercetin for either 3 or 14 days.  It has been suggested that 
bioavailability of flavonoids may be enhanced when combined in supplementation with other 
nutritional bioactives161,195,325.  Indeed, a previous study found enhanced immunomodulatory effect 
post-exercise in cyclists that had been taking Q-EGCG, a supplement combining quercetin with 
vitamin C, isoquercetin, epigallocatechin gallate (EGCG), and n-3 fatty acids, for two weeks daily324. 
One caveat of the in vivo model described herein is that resting peripheral blood cytokine 
measures were not taken.  To do this would have required more mice assigned to each diet serving as 
a non-exercise control.  Without this control, the lack of significant difference in cytokine measures 
between supplemented and placebo diets could be explained by the simple fact that said cytokine may 
have not been elevated above homeostatic levels following exercise.  For instance, no human studies 
have shown an increase in plasma TNF-a immediately following exhaustive exercise, instead only 
reporting increases several hours post-exercise326–330.  Of the seven cytokines measured, only IL-10 
was lower in quercetin supplemented versus control mice immediately following exercise after 
adjusting for weight loss.  IL-10 is a cytokine associated with immunosuppression since it attenuates 
the synthesis of IL-1a, IL-1b, TNF-a, IFN-g, IL-6, IL-8, CCL3, CCL4, G-CSF, and GM-CSF and 
augments IL-1ra production331,332.  Numerous studies have reported elevated plasma IL-10 levels 
immediately following exhaustive exercise18,333–336.  Its downregulation following 14-day quercetin 
supplementation in this study is in agreement with that found in the Q-EGCG chew tested in humans 
after exhaustive cycling.  However, 14-day supplementation with Q-EGCG also decreased post-
exercise levels of plasma IL-6, a finding that was not reproduced in this study268. 
Putative anti-inflammatory effects have also been described in both animal and in vitro 
models testing EGCG, a catechin and predominate polyphenol in green tea extract 216,337–339.  To test 
whether EGCG could be contributing to the enhanced bioactive effects of Q-EGCG, mice in the 
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present study were given quercetin and EGCG at a 5:1 ratio.  This ratio was chosen based on the in 
vitro finding that a high to low proportion of quercetin to EGCG was most effective at blunting LPS-
stimulated TNF-α production in PBMCs.  Furthermore, EGCG was found to dose-dependently 
increase TNF-α production, with a detrimental effect on cell viability at 25 and 50 µM concentrations.  
These results were in agreement with findings by Crouvezier et al. (2000), who also reported EGCG’s 
negligible effect on LPS-stimulated TNF-α production in human PBMCs at concentrations of up to 20 
µM339.  Unfortunately, results from the present animal study shed doubt that the combination of 
flavonoids in Q-EGCG contributed to its effectiveness in human athletes.  In fact, none of the seven 
cytokines measured post-exercise differed between quercetin only treated mice and those receiving a 
5:1 combination of quercetin and EGCG.  Since the in vitro experiment determining the optimal ratio 
of quercetin to EGCG failed to have a quercetin only control, these experiments were repeated using 
25 µM quercetin and 5 µM EGCG, both alone and in combination.  Results from this experiment 
confirm that 5 µM EGCG failed to enhance the anti-inflammatory effect of quercetin in the scope of 
this model. 
Another caveat of this study was that the assessment of anti-inflammatory effectiveness in 
exercised mice was limited to plasma cytokine measures.  In a more recent study of obese women 
supplemented on a mixed flavonoid-nutrient-fish oil supplement (Q-Mix; 1000 mg quercetin, 400 mg 
isoquercetin, 120 mg EGCG from green tea extract, 400 mg n3-PUFAs from fish oil, 1000 mg 
vitamin C, 40 mg niacinamide, and 800 µg folic acid) for 10-weeks, similar biomarkers of 
inflammation (CRP and cytokine panel) were not altered, however further microarray gene expression 
analysis revealed overrepresentation of 27 inflammatory response-related bio-functions in Q-mix 
versus placebo.  Since assessment of anti-inflammatory effectiveness in the current study was limited 
to whole blood cytokine levels, it is conceivable that quercetin may have influenced expression of 
other immunomodulatory genes.  In addition, peripheral blood protein and gene expression fails to 
capture the dynamic paracrine and autocrine signaling occurring between infiltrating leukocytes and 
myofibers in inflamed skeletal muscle tissue. 
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In conclusion, aims accomplished in vitro in this thesis study included comparing quercetin’s 
anti-inflammatory potential to that of biologically relevant quercetin conjugates, and both understand 
and optimize the ratio at which quercetin and EGCG combined exerts the most potent anti-
inflammatory potential.  Analysis conducted on the thesis in vitro data indicated that conjugation with 
either glucuronide or sulfate eliminates quercetin aglycone’s anti-inflammatory effect in vitro.  
However, EGCG exerts a pro-inflammatory effect at high concentrations within this in vitro model 
and, when combined with quercetin aglycone, fails to potentiate quercetin’s anti-inflammatory effect.  
Nevertheless, a 5:1 ratio of quercetin to EGCG was chosen for subsequent testing in an exercising 
mouse model, reasoning that a low dose of EGCG relative to quercetin aglycone would not counteract 
any putative, anti-inflammatory effect of quercetin in vivo.  The in vivo thesis data herein failed to 
demonstrate a requirement for EGCG in substantiating quercetin’s effect on post-exercise 
inflammation in mice.  Furthermore, EGCG at the relative concentrations tested failed to impact the 
bioavailability of quercetin in mice. 
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